search
Back to results

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
dabigatran dose 1
dabigatran dose 2
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

Participation in RE-LY, requires long term anticoagulation, provides written informed consent

Exclusion criteria:

Permanent discontinuation of dabigatran during RE-LY

Sites / Locations

  • 1160.71.0046 Boehringer Ingelheim Investigational Site
  • 1160.71.0057 Boehringer Ingelheim Investigational Site
  • 1160.71.0211 Boehringer Ingelheim Investigational Site
  • 1160.71.0115 Boehringer Ingelheim Investigational Site
  • 1160.71.0104 Boehringer Ingelheim Investigational Site
  • 1160.71.0185 Boehringer Ingelheim Investigational Site
  • 1160.71.0038 Boehringer Ingelheim Investigational Site
  • 1160.71.0302 Boehringer Ingelheim Investigational Site
  • 1160.71.0191 Boehringer Ingelheim Investigational Site
  • 1160.71.0213 Boehringer Ingelheim Investigational Site
  • 1160.71.0441 Boehringer Ingelheim Investigational Site
  • 1160.71.0333 Boehringer Ingelheim Investigational Site
  • 1160.71.0384 Boehringer Ingelheim Investigational Site
  • 1160.71.0246 Boehringer Ingelheim Investigational Site
  • 1160.71.0070 Boehringer Ingelheim Investigational Site
  • 1160.71.0349 Boehringer Ingelheim Investigational Site
  • 1160.71.0016 Boehringer Ingelheim Investigational Site
  • 1160.71.0459 Boehringer Ingelheim Investigational Site
  • 1160.71.0270 Boehringer Ingelheim Investigational Site
  • 1160.71.0135 Boehringer Ingelheim Investigational Site
  • 1160.71.0300 Boehringer Ingelheim Investigational Site
  • 1160.71.0284 Boehringer Ingelheim Investigational Site
  • 1160.71.0379 Boehringer Ingelheim Investigational Site
  • 1160.71.0321 Boehringer Ingelheim Investigational Site
  • 1160.71.0449 Boehringer Ingelheim Investigational Site
  • 1160.71.0360 Boehringer Ingelheim Investigational Site
  • 1160.71.0413 Boehringer Ingelheim Investigational Site
  • 1160.71.0362 Boehringer Ingelheim Investigational Site
  • 1160.71.0278 Boehringer Ingelheim Investigational Site
  • 1160.71.0482 Boehringer Ingelheim Investigational Site
  • 1160.71.0382 Boehringer Ingelheim Investigational Site
  • 1160.71.0056 Boehringer Ingelheim Investigational Site
  • 1160.71.0296 Boehringer Ingelheim Investigational Site
  • 1160.71.0327 Boehringer Ingelheim Investigational Site
  • 1160.71.0376 Boehringer Ingelheim Investigational Site
  • 1160.71.0074 Boehringer Ingelheim Investigational Site
  • 1160.71.0089 Boehringer Ingelheim Investigational Site
  • 1160.71.0232 Boehringer Ingelheim Investigational Site
  • 1160.71.0427 Boehringer Ingelheim Investigational Site
  • 1160.71.0012 Boehringer Ingelheim Investigational Site
  • 1160.71.0034 Boehringer Ingelheim Investigational Site
  • 1160.71.0227 Boehringer Ingelheim Investigational Site
  • 1160.71.0095 Boehringer Ingelheim Investigational Site
  • 1160.71.0037 Boehringer Ingelheim Investigational Site
  • 1160.71.0137 Boehringer Ingelheim Investigational Site
  • 1160.71.0417 Boehringer Ingelheim Investigational Site
  • 1160.71.0332 Boehringer Ingelheim Investigational Site
  • 1160.71.0385 Boehringer Ingelheim Investigational Site
  • 1160.71.0015 Boehringer Ingelheim Investigational Site
  • 1160.71.0339 Boehringer Ingelheim Investigational Site
  • 1160.71.0019 Boehringer Ingelheim Investigational Site
  • 1160.71.0159 Boehringer Ingelheim Investigational Site
  • 1160.71.0021 Boehringer Ingelheim Investigational Site
  • 1160.71.0161 Boehringer Ingelheim Investigational Site
  • 1160.71.0218 Boehringer Ingelheim Investigational Site
  • 1160.71.0438 Boehringer Ingelheim Investigational Site
  • 1160.71.0331 Boehringer Ingelheim Investigational Site
  • 1160.71.0364 Boehringer Ingelheim Investigational Site
  • 1160.71.0109 Boehringer Ingelheim Investigational Site
  • 1160.71.0152 Boehringer Ingelheim Investigational Site
  • 1160.71.0198 Boehringer Ingelheim Investigational Site
  • 1160.71.0433 Boehringer Ingelheim Investigational Site
  • 1160.71.0377 Boehringer Ingelheim Investigational Site
  • 1160.71.0288 Boehringer Ingelheim Investigational Site
  • 1160.71.0352 Boehringer Ingelheim Investigational Site
  • 1160.71.0436 Boehringer Ingelheim Investigational Site
  • 1160.71.0235 Boehringer Ingelheim Investigational Site
  • 1160.71.0268 Boehringer Ingelheim Investigational Site
  • 1160.71.0001 Boehringer Ingelheim Investigational Site
  • 1160.71.0357 Boehringer Ingelheim Investigational Site
  • 1160.71.0422 Boehringer Ingelheim Investigational Site
  • 1160.71.0178 Boehringer Ingelheim Investigational Site
  • 1160.71.0397 Boehringer Ingelheim Investigational Site
  • 1160.71.0310 Boehringer Ingelheim Investigational Site
  • 1160.71.0144 Boehringer Ingelheim Investigational Site
  • 1160.71.0018 Boehringer Ingelheim Investigational Site
  • 1160.71.0132 Boehringer Ingelheim Investigational Site
  • 1160.71.0096 Boehringer Ingelheim Investigational Site
  • 1160.71.0114 Boehringer Ingelheim Investigational Site
  • 1160.71.0023 Boehringer Ingelheim Investigational Site
  • 1160.71.0047 Boehringer Ingelheim Investigational Site
  • 1160.71.0079 Boehringer Ingelheim Investigational Site
  • 1160.71.0186 Boehringer Ingelheim Investigational Site
  • 1160.71.0194 Boehringer Ingelheim Investigational Site
  • 1160.71.0255 Boehringer Ingelheim Investigational Site
  • 1160.71.0398 Boehringer Ingelheim Investigational Site
  • 1160.71.0177 Boehringer Ingelheim Investigational Site
  • 1160.71.0073 Boehringer Ingelheim Investigational Site
  • 1160.71.0207 Boehringer Ingelheim Investigational Site
  • 1160.71.0196 Boehringer Ingelheim Investigational Site
  • 1160.71.0187 Boehringer Ingelheim Investigational Site
  • 1160.71.0052 Boehringer Ingelheim Investigational Site
  • 1160.71.0443 Boehringer Ingelheim Investigational Site
  • 1160.71.0452 Boehringer Ingelheim Investigational Site
  • 1160.71.0029 Boehringer Ingelheim Investigational Site
  • 1160.71.0003 Boehringer Ingelheim Investigational Site
  • 1160.71.0308 Boehringer Ingelheim Investigational Site
  • 1160.71.0154 Boehringer Ingelheim Investigational Site
  • 1160.71.0205 Boehringer Ingelheim Investigational Site
  • 1160.71.0279 Boehringer Ingelheim Investigational Site
  • 1160.71.0445 Boehringer Ingelheim Investigational Site
  • 1160.71.0274 Boehringer Ingelheim Investigational Site
  • 1160.71.0165 Boehringer Ingelheim Investigational Site
  • 1160.71.0020 Boehringer Ingelheim Investigational Site
  • 1160.71.0188 Boehringer Ingelheim Investigational Site
  • 1160.71.0202 Boehringer Ingelheim Investigational Site
  • 1160.71.0101 Boehringer Ingelheim Investigational Site
  • 1160.71.0086 Boehringer Ingelheim Investigational Site
  • 1160.71.0119 Boehringer Ingelheim Investigational Site
  • 1160.71.0055 Boehringer Ingelheim Investigational Site
  • 1160.71.0257 Boehringer Ingelheim Investigational Site
  • 1160.71.0336 Boehringer Ingelheim Investigational Site
  • 1160.71.0249 Boehringer Ingelheim Investigational Site
  • 1160.71.0027 Boehringer Ingelheim Investigational Site
  • 1160.71.0110 Boehringer Ingelheim Investigational Site
  • 1160.71.0346 Boehringer Ingelheim Investigational Site
  • 1160.71.0430 Boehringer Ingelheim Investigational Site
  • 1160.71.0142 Boehringer Ingelheim Investigational Site
  • 1160.71.0221 Boehringer Ingelheim Investigational Site
  • 1160.71.0248 Boehringer Ingelheim Investigational Site
  • 1160.71.0478 Boehringer Ingelheim Investigational Site
  • 1160.71.0392 Boehringer Ingelheim Investigational Site
  • 1160.71.0254 Boehringer Ingelheim Investigational Site
  • 1160.71.0472 Boehringer Ingelheim Investigational Site
  • 1160.71.0476 Boehringer Ingelheim Investigational Site
  • 1160.71.0113 Boehringer Ingelheim Investigational Site
  • 1160.71.0281 Boehringer Ingelheim Investigational Site
  • 1160.71.0044 Boehringer Ingelheim Investigational Site
  • 1160.71.0229 Boehringer Ingelheim Investigational Site
  • 1160.71.0451 Boehringer Ingelheim Investigational Site
  • 1160.71.0183 Boehringer Ingelheim Investigational Site
  • 1160.71.0210 Boehringer Ingelheim Investigational Site
  • 1160.71.0075 Boehringer Ingelheim Investigational Site
  • 1160.71.0414 Boehringer Ingelheim Investigational Site
  • 1160.71.0356 Boehringer Ingelheim Investigational Site
  • 1160.71.0064 Boehringer Ingelheim Investigational Site
  • 1160.71.0353 Boehringer Ingelheim Investigational Site
  • 1160.71.0080 Boehringer Ingelheim Investigational Site
  • 1160.71.0350 Boehringer Ingelheim Investigational Site
  • 1160.71.0173 Boehringer Ingelheim Investigational Site
  • 1160.71.0006 Boehringer Ingelheim Investigational Site
  • 1160.71.0002 Boehringer Ingelheim Investigational Site
  • 1160.71.0069 Boehringer Ingelheim Investigational Site
  • 1160.71.0102 Boehringer Ingelheim Investigational Site
  • 1160.71.0222 Boehringer Ingelheim Investigational Site
  • 1160.71.0203 Boehringer Ingelheim Investigational Site
  • 1160.71.0434 Boehringer Ingelheim Investigational Site
  • 1160.71.0402 Boehringer Ingelheim Investigational Site
  • 1160.71.0426 Boehringer Ingelheim Investigational Site
  • 1160.71.0479 Boehringer Ingelheim Investigational Site
  • 1160.71.0263 Boehringer Ingelheim Investigational Site
  • 1160.71.0480 Boehringer Ingelheim Investigational Site
  • 1160.71.0267 Boehringer Ingelheim Investigational Site
  • 1160.71.0035 Boehringer Ingelheim Investigational Site
  • 1160.71.0150 Boehringer Ingelheim Investigational Site
  • 1160.71.0201 Boehringer Ingelheim Investigational Site
  • 1160.71.0223 Boehringer Ingelheim Investigational Site
  • 1160.71.0214 Boehringer Ingelheim Investigational Site
  • 1160.71.0275 Boehringer Ingelheim Investigational Site
  • 1160.71.0103 Boehringer Ingelheim Investigational Site
  • 1160.71.0435 Boehringer Ingelheim Investigational Site
  • 1160.71.0139 Boehringer Ingelheim Investigational Site
  • 1160.71.0325 Boehringer Ingelheim Investigational Site
  • 1160.71.0133 Boehringer Ingelheim Investigational Site
  • 1160.71.0301 Boehringer Ingelheim Investigational Site
  • 1160.71.0295 Boehringer Ingelheim Investigational Site
  • 1160.71.0294 Boehringer Ingelheim Investigational Site
  • 1160.71.0369 Boehringer Ingelheim Investigational Site
  • 1160.71.0431 Boehringer Ingelheim Investigational Site
  • 1160.71.0168 Boehringer Ingelheim Investigational Site
  • 1160.71.0293 Boehringer Ingelheim Investigational Site
  • 1160.71.0394 Boehringer Ingelheim Investigational Site
  • 1160.71.0466 Boehringer Ingelheim Investigational Site
  • 1160.71.0208 Boehringer Ingelheim Investigational Site
  • 1160.71.0465 Boehringer Ingelheim Investigational Site
  • 1160.71.0032 Boehringer Ingelheim Investigational Site
  • 1160.71.0067 Boehringer Ingelheim Investigational Site
  • 1160.71.0007 Boehringer Ingelheim Investigational Site
  • 1160.71.0383 Boehringer Ingelheim Investigational Site
  • 1160.71.0313 Boehringer Ingelheim Investigational Site
  • 1160.71.0166 Boehringer Ingelheim Investigational Site
  • 1160.71.0008 Boehringer Ingelheim Investigational Site
  • 1160.71.0084 Boehringer Ingelheim Investigational Site
  • 1160.71.0474 Boehringer Ingelheim Investigational Site
  • 1160.71.0062 Boehringer Ingelheim Investigational Site
  • 1160.71.0370 Boehringer Ingelheim Investigational Site
  • 1160.71.0395 Boehringer Ingelheim Investigational Site
  • 1160.71.0129 Boehringer Ingelheim Investigational Site
  • 1160.71.0410 Boehringer Ingelheim Investigational Site
  • 1160.71.0156 Boehringer Ingelheim Investigational Site
  • 1160.71.0315 Boehringer Ingelheim Investigational Site
  • 1160.71.0447 Boehringer Ingelheim Investigational Site
  • 1160.71.0483 Boehringer Ingelheim Investigational Site
  • 1160.71.0335 Boehringer Ingelheim Investigational Site
  • 1160.71.0269 Boehringer Ingelheim Investigational Site
  • 1160.71.0307 Boehringer Ingelheim Investigational Site
  • 1160.71.0285 Boehringer Ingelheim Investigational Site
  • 1160.71.0367 Boehringer Ingelheim Investigational Site
  • 1160.71.0453 Boehringer Ingelheim Investigational Site
  • 1160.71.0053 Boehringer Ingelheim Investigational Site
  • 1160.71.0428 Boehringer Ingelheim Investigational Site
  • 1160.71.0311 Boehringer Ingelheim Investigational Site
  • 1160.71.0292 Boehringer Ingelheim Investigational Site
  • 1160.71.0220 Boehringer Ingelheim Investigational Site
  • 1160.71.0224 Boehringer Ingelheim Investigational Site
  • 1160.71.0317 Boehringer Ingelheim Investigational Site
  • 1160.71.0050 Boehringer Ingelheim Investigational Site
  • 1160.71.0040 Boehringer Ingelheim Investigational Site
  • 1160.71.0250 Boehringer Ingelheim Investigational Site
  • 1160.71.0256 Boehringer Ingelheim Investigational Site
  • 1160.71.0024 Boehringer Ingelheim Investigational Site
  • 1160.71.0169 Boehringer Ingelheim Investigational Site
  • 1160.71.0365 Boehringer Ingelheim Investigational Site
  • 1160.71.0099 Boehringer Ingelheim Investigational Site
  • 1160.71.0072 Boehringer Ingelheim Investigational Site
  • 1160.71.0461 Boehringer Ingelheim Investigational Site
  • 1160.71.0508 Boehringer Ingelheim Investigational Site
  • 1160.71.0510 Boehringer Ingelheim Investigational Site
  • 1160.71.0506 Boehringer Ingelheim Investigational Site
  • 1160.71.0509 Boehringer Ingelheim Investigational Site
  • 1160.71.0507 Boehringer Ingelheim Investigational Site
  • 1160.71.0504 Boehringer Ingelheim Investigational Site
  • 1160.71.0501 Boehringer Ingelheim Investigational Site
  • 1160.71.0543 Boehringer Ingelheim Investigational Site
  • 1160.71.0549 Boehringer Ingelheim Investigational Site
  • 1160.71.0541 Boehringer Ingelheim Investigational Site
  • 1160.71.0542 Boehringer Ingelheim Investigational Site
  • 1160.71.0545 Boehringer Ingelheim Investigational Site
  • 1160.71.0547 Boehringer Ingelheim Investigational Site
  • 1160.71.0548 Boehringer Ingelheim Investigational Site
  • 1160.71.0550 Boehringer Ingelheim Investigational Site
  • 1160.71.0564 Boehringer Ingelheim Investigational Site
  • 1160.71.0572 Boehringer Ingelheim Investigational Site
  • 1160.71.0571 Boehringer Ingelheim Investigational Site
  • 1160.71.0581 Boehringer Ingelheim Investigational Site
  • 1160.71.0585 Boehringer Ingelheim Investigational Site
  • 1160.71.0563 Boehringer Ingelheim Investigational Site
  • 1160.71.0578 Boehringer Ingelheim Investigational Site
  • 1160.71.0587 Boehringer Ingelheim Investigational Site
  • 1160.71.0574 Boehringer Ingelheim Investigational Site
  • 1160.71.0588 Boehringer Ingelheim Investigational Site
  • 1160.71.0568 Boehringer Ingelheim Investigational Site
  • 1160.71.0561 Boehringer Ingelheim Investigational Site
  • 1160.71.0579 Boehringer Ingelheim Investigational Site
  • 1160.71.0567 Boehringer Ingelheim Investigational Site
  • 1160.71.0570 Boehringer Ingelheim Investigational Site
  • 1160.71.0566 Boehringer Ingelheim Investigational Site
  • 1160.71.0562 Boehringer Ingelheim Investigational Site
  • 1160.71.0644 Boehringer Ingelheim Investigational Site
  • 1160.71.0650 Boehringer Ingelheim Investigational Site
  • 1160.71.0651 Boehringer Ingelheim Investigational Site
  • 1160.71.0652 Boehringer Ingelheim Investigational Site
  • 1160.71.0646 Boehringer Ingelheim Investigational Site
  • 1160.71.0647 Boehringer Ingelheim Investigational Site
  • 1160.71.0643 Boehringer Ingelheim Investigational Site
  • 1160.71.0620 Boehringer Ingelheim Investigational Site
  • 1160.71.0611 Boehringer Ingelheim Investigational Site
  • 1160.71.0612 Boehringer Ingelheim Investigational Site
  • 1160.71.0615 Boehringer Ingelheim Investigational Site
  • 1160.71.0617 Boehringer Ingelheim Investigational Site
  • 1160.71.0618 Boehringer Ingelheim Investigational Site
  • 1160.71.0625 Boehringer Ingelheim Investigational Site
  • 1160.71.0694 Boehringer Ingelheim Investigational Site
  • 1160.71.0696 Boehringer Ingelheim Investigational Site
  • 1160.71.0680 Boehringer Ingelheim Investigational Site
  • 1160.71.0712 Boehringer Ingelheim Investigational Site
  • 1160.71.0706 Boehringer Ingelheim Investigational Site
  • 1160.71.0725 Boehringer Ingelheim Investigational Site
  • 1160.71.0691 Boehringer Ingelheim Investigational Site
  • 1160.71.0714 Boehringer Ingelheim Investigational Site
  • 1160.71.0701 Boehringer Ingelheim Investigational Site
  • 1160.71.0703 Boehringer Ingelheim Investigational Site
  • 1160.71.0674 Boehringer Ingelheim Investigational Site
  • 1160.71.0702 Boehringer Ingelheim Investigational Site
  • 1160.71.0720 Boehringer Ingelheim Investigational Site
  • 1160.71.0692 Boehringer Ingelheim Investigational Site
  • 1160.71.0697 Boehringer Ingelheim Investigational Site
  • 1160.71.0710 Boehringer Ingelheim Investigational Site
  • 1160.71.0719 Boehringer Ingelheim Investigational Site
  • 1160.71.0721 Boehringer Ingelheim Investigational Site
  • 1160.71.0708 Boehringer Ingelheim Investigational Site
  • 1160.71.0688 Boehringer Ingelheim Investigational Site
  • 1160.71.0672 Boehringer Ingelheim Investigational Site
  • 1160.71.0687 Boehringer Ingelheim Investigational Site
  • 1160.71.0679 Boehringer Ingelheim Investigational Site
  • 1160.71.0723 Boehringer Ingelheim Investigational Site
  • 1160.71.0715 Boehringer Ingelheim Investigational Site
  • 1160.71.0690 Boehringer Ingelheim Investigational Site
  • 1160.71.0684 Boehringer Ingelheim Investigational Site
  • 1160.71.0718 Boehringer Ingelheim Investigational Site
  • 1160.71.0686 Boehringer Ingelheim Investigational Site
  • 1160.71.0683 Boehringer Ingelheim Investigational Site
  • 1160.71.0705 Boehringer Ingelheim Investigational Site
  • 1160.71.0709 Boehringer Ingelheim Investigational Site
  • 1160.71.0716 Boehringer Ingelheim Investigational Site
  • 1160.71.0717 Boehringer Ingelheim Investigational Site
  • 1160.71.0699 Boehringer Ingelheim Investigational Site
  • 1160.71.0713 Boehringer Ingelheim Investigational Site
  • 1160.71.0675 Boehringer Ingelheim Investigational Site
  • 1160.71.0673 Boehringer Ingelheim Investigational Site
  • 1160.71.0678 Boehringer Ingelheim Investigational Site
  • 1160.71.0700 Boehringer Ingelheim Investigational Site
  • 1160.71.0771 Boehringer Ingelheim Investigational Site
  • 1160.71.0772 Boehringer Ingelheim Investigational Site
  • 1160.71.0773 Boehringer Ingelheim Investigational Site
  • 1160.71.0774 Boehringer Ingelheim Investigational Site
  • 1160.71.0776 Boehringer Ingelheim Investigational Site
  • 1160.71.0784 Boehringer Ingelheim Investigational Site
  • 1160.71.0778 Boehringer Ingelheim Investigational Site
  • 1160.71.0781 Boehringer Ingelheim Investigational Site
  • 1160.71.0782 Boehringer Ingelheim Investigational Site
  • 1160.71.0777 Boehringer Ingelheim Investigational Site
  • 1160.71.0780 Boehringer Ingelheim Investigational Site
  • 1160.71.0816 Boehringer Ingelheim Investigational Site
  • 1160.71.0820 Boehringer Ingelheim Investigational Site
  • 1160.71.0818 Boehringer Ingelheim Investigational Site
  • 1160.71.0814 Boehringer Ingelheim Investigational Site
  • 1160.71.0811 Boehringer Ingelheim Investigational Site
  • 1160.71.0812 Boehringer Ingelheim Investigational Site
  • 1160.71.0813 Boehringer Ingelheim Investigational Site
  • 1160.71.0817 Boehringer Ingelheim Investigational Site
  • 1160.71.0819 Boehringer Ingelheim Investigational Site
  • 1160.71.0837 Boehringer Ingelheim Investigational Site
  • 1160.71.0835 Boehringer Ingelheim Investigational Site
  • 1160.71.0838 Boehringer Ingelheim Investigational Site
  • 1160.71.0833 Boehringer Ingelheim Investigational Site
  • 1160.71.0834 Boehringer Ingelheim Investigational Site
  • 1160.71.0841 Boehringer Ingelheim Investigational Site
  • 1160.71.0832 Boehringer Ingelheim Investigational Site
  • 1160.71.0840 Boehringer Ingelheim Investigational Site
  • 1160.71.0831 Boehringer Ingelheim Investigational Site
  • 1160.71.0839 Boehringer Ingelheim Investigational Site
  • 1160.71.0836 Boehringer Ingelheim Investigational Site
  • 1160.71.0851 Boehringer Ingelheim Investigational Site
  • 1160.71.0859 Boehringer Ingelheim Investigational Site
  • 1160.71.0854 Boehringer Ingelheim Investigational Site
  • 1160.71.0858 Boehringer Ingelheim Investigational Site
  • 1160.71.0852 Boehringer Ingelheim Investigational Site
  • 1160.71.0853 Boehringer Ingelheim Investigational Site
  • 1160.71.875A Boehringer Ingelheim Investigational Site
  • 1160.71.882D Boehringer Ingelheim Investigational Site
  • 1160.71.882G Boehringer Ingelheim Investigational Site
  • 1160.71.879F Boehringer Ingelheim Investigational Site
  • 1160.71.887A Boehringer Ingelheim Investigational Site
  • 1160.71.882K Boehringer Ingelheim Investigational Site
  • 1160.71.879C Boehringer Ingelheim Investigational Site
  • 1160.71.882H Boehringer Ingelheim Investigational Site
  • 1160.71.888A Boehringer Ingelheim Investigational Site
  • 1160.71.879B Boehringer Ingelheim Investigational Site
  • 1160.71.874A Boehringer Ingelheim Investigational Site
  • 1160.71.884A Boehringer Ingelheim Investigational Site
  • 1160.71.880B Boehringer Ingelheim Investigational Site
  • 1160.71.880A Boehringer Ingelheim Investigational Site
  • 1160.71.879A Boehringer Ingelheim Investigational Site
  • 1160.71.879H Boehringer Ingelheim Investigational Site
  • 1160.71.879S Boehringer Ingelheim Investigational Site
  • 1160.71.880J Boehringer Ingelheim Investigational Site
  • 1160.71.871A Boehringer Ingelheim Investigational Site
  • 1160.71.879E Boehringer Ingelheim Investigational Site
  • 1160.71.880D Boehringer Ingelheim Investigational Site
  • 1160.71.882A Boehringer Ingelheim Investigational Site
  • 1160.71.882B Boehringer Ingelheim Investigational Site
  • 1160.71.882C Boehringer Ingelheim Investigational Site
  • 1160.71.879G Boehringer Ingelheim Investigational Site
  • 1160.71.880E Boehringer Ingelheim Investigational Site
  • 1160.71.0932 Boehringer Ingelheim Investigational Site
  • 1160.71.0948 Boehringer Ingelheim Investigational Site
  • 1160.71.0962 Boehringer Ingelheim Investigational Site
  • 1160.71.0940 Boehringer Ingelheim Investigational Site
  • 1160.71.0972 Boehringer Ingelheim Investigational Site
  • 1160.71.0934 Boehringer Ingelheim Investigational Site
  • 1160.71.0931 Boehringer Ingelheim Investigational Site
  • 1160.71.0943 Boehringer Ingelheim Investigational Site
  • 1160.71.0963 Boehringer Ingelheim Investigational Site
  • 1160.71.0946 Boehringer Ingelheim Investigational Site
  • 1160.71.0944 Boehringer Ingelheim Investigational Site
  • 1160.71.0951 Boehringer Ingelheim Investigational Site
  • 1160.71.0933 Boehringer Ingelheim Investigational Site
  • 1160.71.0945 Boehringer Ingelheim Investigational Site
  • 1160.71.0970 Boehringer Ingelheim Investigational Site
  • 1160.71.0937 Boehringer Ingelheim Investigational Site
  • 1160.71.0966 Boehringer Ingelheim Investigational Site
  • 1160.71.0901 Boehringer Ingelheim Investigational Site
  • 1160.71.0914 Boehringer Ingelheim Investigational Site
  • 1160.71.0904 Boehringer Ingelheim Investigational Site
  • 1160.71.0910 Boehringer Ingelheim Investigational Site
  • 1160.71.0903 Boehringer Ingelheim Investigational Site
  • 1160.71.0905 Boehringer Ingelheim Investigational Site
  • 1160.71.1003 Boehringer Ingelheim Investigational Site
  • 1160.71.1004 Boehringer Ingelheim Investigational Site
  • 1160.71.1011 Boehringer Ingelheim Investigational Site
  • 1160.71.1012 Boehringer Ingelheim Investigational Site
  • 1160.71.1013 Boehringer Ingelheim Investigational Site
  • 1160.71.1014 Boehringer Ingelheim Investigational Site
  • 1160.71.1015 Boehringer Ingelheim Investigational Site
  • 1160.71.1016 Boehringer Ingelheim Investigational Site
  • 1160.71.1020 Boehringer Ingelheim Investigational Site
  • 1160.71.1017 Boehringer Ingelheim Investigational Site
  • 1160.71.1018 Boehringer Ingelheim Investigational Site
  • 1160.71.1056 Boehringer Ingelheim Investigational Site
  • 1160.71.1057 Boehringer Ingelheim Investigational Site
  • 1160.71.1065 Boehringer Ingelheim Investigational Site
  • 1160.71.1062 Boehringer Ingelheim Investigational Site
  • 1160.71.1073 Boehringer Ingelheim Investigational Site
  • 1160.71.1067 Boehringer Ingelheim Investigational Site
  • 1160.71.1068 Boehringer Ingelheim Investigational Site
  • 1160.71.1055 Boehringer Ingelheim Investigational Site
  • 1160.71.1051 Boehringer Ingelheim Investigational Site
  • 1160.71.1072 Boehringer Ingelheim Investigational Site
  • 1160.71.1059 Boehringer Ingelheim Investigational Site
  • 1160.71.1052 Boehringer Ingelheim Investigational Site
  • 1160.71.1070 Boehringer Ingelheim Investigational Site
  • 1160.71.1110 Boehringer Ingelheim Investigational Site
  • 1160.71.1121 Boehringer Ingelheim Investigational Site
  • 1160.71.1111 Boehringer Ingelheim Investigational Site
  • 1160.71.1117 Boehringer Ingelheim Investigational Site
  • 1160.71.1112 Boehringer Ingelheim Investigational Site
  • 1160.71.1091 Boehringer Ingelheim Investigational Site
  • 1160.71.1113 Boehringer Ingelheim Investigational Site
  • 1160.71.1114 Boehringer Ingelheim Investigational Site
  • 1160.71.1116 Boehringer Ingelheim Investigational Site
  • 1160.71.1118 Boehringer Ingelheim Investigational Site
  • 1160.71.1105 Boehringer Ingelheim Investigational Site
  • 1160.71.1101 Boehringer Ingelheim Investigational Site
  • 1160.71.1104 Boehringer Ingelheim Investigational Site
  • 1160.71.1106 Boehringer Ingelheim Investigational Site
  • 1160.71.1119 Boehringer Ingelheim Investigational Site
  • 1160.71.1096 Boehringer Ingelheim Investigational Site
  • 1160.71.1093 Boehringer Ingelheim Investigational Site
  • 1160.71.1094 Boehringer Ingelheim Investigational Site
  • 1160.71.1095 Boehringer Ingelheim Investigational Site
  • 1160.71.1100 Boehringer Ingelheim Investigational Site
  • 1160.71.1103 Boehringer Ingelheim Investigational Site
  • 1160.71.1120 Boehringer Ingelheim Investigational Site
  • 1160.71.1122 Boehringer Ingelheim Investigational Site
  • 1160.71.1107 Boehringer Ingelheim Investigational Site
  • 1160.71.1108 Boehringer Ingelheim Investigational Site
  • 1160.71.1109 Boehringer Ingelheim Investigational Site
  • 1160.71.1169 Boehringer Ingelheim Investigational Site
  • 1160.71.1172 Boehringer Ingelheim Investigational Site
  • 1160.71.1170 Boehringer Ingelheim Investigational Site
  • 1160.71.1585 Boehringer Ingelheim Investigational Site
  • 1160.71.1586 Boehringer Ingelheim Investigational Site
  • 1160.71.1584 Boehringer Ingelheim Investigational Site
  • 1160.71.1591 Boehringer Ingelheim Investigational Site
  • 1160.71.1590 Boehringer Ingelheim Investigational Site
  • 1160.71.1581 Boehringer Ingelheim Investigational Site
  • 1160.71.1582 Boehringer Ingelheim Investigational Site
  • 1160.71.1583 Boehringer Ingelheim Investigational Site
  • 1160.71.1589 Boehringer Ingelheim Investigational Site
  • 1160.71.1592 Boehringer Ingelheim Investigational Site
  • 1160.71.1593 Boehringer Ingelheim Investigational Site
  • 1160.71.1291 Boehringer Ingelheim Investigational Site
  • 1160.71.1292 Boehringer Ingelheim Investigational Site
  • 1160.71.1337 Boehringer Ingelheim Investigational Site
  • 1160.71.1344 Boehringer Ingelheim Investigational Site
  • 1160.71.1331 Boehringer Ingelheim Investigational Site
  • 1160.71.1336 Boehringer Ingelheim Investigational Site
  • 1160.71.1332 Boehringer Ingelheim Investigational Site
  • 1160.71.1349 Boehringer Ingelheim Investigational Site
  • 1160.71.1345 Boehringer Ingelheim Investigational Site
  • 1160.71.1360 Boehringer Ingelheim Investigational Site
  • 1160.71.1340 Boehringer Ingelheim Investigational Site
  • 1160.71.1358 Boehringer Ingelheim Investigational Site
  • 1160.71.1338 Boehringer Ingelheim Investigational Site
  • 1160.71.1343 Boehringer Ingelheim Investigational Site
  • 1160.71.1347 Boehringer Ingelheim Investigational Site
  • 1160.71.1333 Boehringer Ingelheim Investigational Site
  • 1160.71.1361 Boehringer Ingelheim Investigational Site
  • 1160.71.1339 Boehringer Ingelheim Investigational Site
  • 1160.71.1346 Boehringer Ingelheim Investigational Site
  • 1160.71.1356 Boehringer Ingelheim Investigational Site
  • 1160.71.1359 Boehringer Ingelheim Investigational Site
  • 1160.71.1341 Boehringer Ingelheim Investigational Site
  • 1160.71.1354 Boehringer Ingelheim Investigational Site
  • 1160.71.1351 Boehringer Ingelheim Investigational Site
  • 1160.71.1353 Boehringer Ingelheim Investigational Site
  • 1160.71.1352 Boehringer Ingelheim Investigational Site
  • 1160.71.1350 Boehringer Ingelheim Investigational Site
  • 1160.71.1342 Boehringer Ingelheim Investigational Site
  • 1160.71.1348 Boehringer Ingelheim Investigational Site
  • 1160.71.1396 Boehringer Ingelheim Investigational Site
  • 1160.71.1393 Boehringer Ingelheim Investigational Site
  • 1160.71.1395 Boehringer Ingelheim Investigational Site
  • 1160.71.1391 Boehringer Ingelheim Investigational Site
  • 1160.71.1397 Boehringer Ingelheim Investigational Site
  • 1160.71.1394 Boehringer Ingelheim Investigational Site
  • 1160.71.1422 Boehringer Ingelheim Investigational Site
  • 1160.71.1421 Boehringer Ingelheim Investigational Site
  • 1160.71.1424 Boehringer Ingelheim Investigational Site
  • 1160.71.1423 Boehringer Ingelheim Investigational Site
  • 1160.71.1425 Boehringer Ingelheim Investigational Site
  • 1160.71.1436 Boehringer Ingelheim Investigational Site
  • 1160.71.1437 Boehringer Ingelheim Investigational Site
  • 1160.71.1438 Boehringer Ingelheim Investigational Site
  • 1160.71.1433 Boehringer Ingelheim Investigational Site
  • 1160.71.1431 Boehringer Ingelheim Investigational Site
  • 1160.71.1432 Boehringer Ingelheim Investigational Site
  • 1160.71.1434 Boehringer Ingelheim Investigational Site
  • 1160.71.1456 Boehringer Ingelheim Investigational Site
  • 1160.71.1451 Boehringer Ingelheim Investigational Site
  • 1160.71.1454 Boehringer Ingelheim Investigational Site
  • 1160.71.1459 Boehringer Ingelheim Investigational Site
  • 1160.71.1457 Boehringer Ingelheim Investigational Site
  • 1160.71.1455 Boehringer Ingelheim Investigational Site
  • 1160.71.1471 Boehringer Ingelheim Investigational Site
  • 1160.71.1472 Boehringer Ingelheim Investigational Site
  • 1160.71.1501 Boehringer Ingelheim Investigational Site
  • 1160.71.1503 Boehringer Ingelheim Investigational Site
  • 1160.71.1504 Boehringer Ingelheim Investigational Site
  • 1160.71.1505 Boehringer Ingelheim Investigational Site
  • 1160.71.1507 Boehringer Ingelheim Investigational Site
  • 1160.71.1508 Boehringer Ingelheim Investigational Site
  • 1160.71.1509 Boehringer Ingelheim Investigational Site
  • 1160.71.1510 Boehringer Ingelheim Investigational Site
  • 1160.71.1511 Boehringer Ingelheim Investigational Site
  • 1160.71.1512 Boehringer Ingelheim Investigational Site
  • 1160.71.1513 Boehringer Ingelheim Investigational Site
  • 1160.71.1514 Boehringer Ingelheim Investigational Site
  • 1160.71.1531 Boehringer Ingelheim Investigational Site
  • 1160.71.1548 Boehringer Ingelheim Investigational Site
  • 1160.71.1541 Boehringer Ingelheim Investigational Site
  • 1160.71.1542 Boehringer Ingelheim Investigational Site
  • 1160.71.1543 Boehringer Ingelheim Investigational Site
  • 1160.71.1550 Boehringer Ingelheim Investigational Site
  • 1160.71.1547 Boehringer Ingelheim Investigational Site
  • 1160.71.1633 Boehringer Ingelheim Investigational Site
  • 1160.71.1627 Boehringer Ingelheim Investigational Site
  • 1160.71.1625 Boehringer Ingelheim Investigational Site
  • 1160.71.1628 Boehringer Ingelheim Investigational Site
  • 1160.71.1626 Boehringer Ingelheim Investigational Site
  • 1160.71.1634 Boehringer Ingelheim Investigational Site
  • 1160.71.1624 Boehringer Ingelheim Investigational Site
  • 1160.71.1621 Boehringer Ingelheim Investigational Site
  • 1160.71.1635 Boehringer Ingelheim Investigational Site
  • 1160.71.1622 Boehringer Ingelheim Investigational Site
  • 1160.71.1623 Boehringer Ingelheim Investigational Site
  • 1160.71.1652 Boehringer Ingelheim Investigational Site
  • 1160.71.1655 Boehringer Ingelheim Investigational Site
  • 1160.71.1651 Boehringer Ingelheim Investigational Site
  • 1160.71.1654 Boehringer Ingelheim Investigational Site
  • 1160.71.1680 Boehringer Ingelheim Investigational Site
  • 1160.71.1683 Boehringer Ingelheim Investigational Site
  • 1160.71.1682 Boehringer Ingelheim Investigational Site
  • 1160.71.1679 Boehringer Ingelheim Investigational Site
  • 1160.71.1681 Boehringer Ingelheim Investigational Site
  • 1160.71.1671 Boehringer Ingelheim Investigational Site
  • 1160.71.1672 Boehringer Ingelheim Investigational Site
  • 1160.71.1673 Boehringer Ingelheim Investigational Site
  • 1160.71.1674 Boehringer Ingelheim Investigational Site
  • 1160.71.1675 Boehringer Ingelheim Investigational Site
  • 1160.71.1676 Boehringer Ingelheim Investigational Site
  • 1160.71.1677 Boehringer Ingelheim Investigational Site
  • 1160.71.1678 Boehringer Ingelheim Investigational Site
  • 1160.71.1701 Boehringer Ingelheim Investigational Site
  • 1160.71.1703 Boehringer Ingelheim Investigational Site
  • 1160.71.1704 Boehringer Ingelheim Investigational Site
  • 1160.71.1744 Boehringer Ingelheim Investigational Site
  • 1160.71.1746 Boehringer Ingelheim Investigational Site
  • 1160.71.1745 Boehringer Ingelheim Investigational Site
  • 1160.71.1755 Boehringer Ingelheim Investigational Site
  • 1160.71.1741 Boehringer Ingelheim Investigational Site
  • 1160.71.1742 Boehringer Ingelheim Investigational Site
  • 1160.71.1751 Boehringer Ingelheim Investigational Site
  • 1160.71.1752 Boehringer Ingelheim Investigational Site
  • 1160.71.1743 Boehringer Ingelheim Investigational Site
  • 1160.71.1748 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

dabigatran dose 1

dabigatran dose 2

Arm Description

dabigatran high dose twice daily

dabigatran low dose twice daily

Outcomes

Primary Outcome Measures

Major Bleeding, Annualized Rate of Subjects With Major Bleeds
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Major bleeding must have satisfied one or more of the following criteria: Bleeding associated with a reduction in hemoglobin of at least 20 g/L Required transfusion of at least 2 units of blood or packed cells Symptomatic bleeding in a critical area or organ: intraocular, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intra-articular, pericardial, gastrointestinal Major bleed were classified as life-threatening if they met one or more of the following criteria: Reduction in hemoglobin of at least 50 g/L Transfusion of at least 4 units of blood or packed cells Symptomatic intracranial bleeding, either subdural or intracerebral Associated with hypotension requiring use of intravenous inotropic agents Required surgical intervention to stop bleeding Resulted in death

Secondary Outcome Measures

Stroke, Annualized Rate of Subjects With Stroke
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Stroke was an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke was categorized as ischemic or hemorrhagic or cause unknown based on computerized tomography (CT), magnetic resonance (MR) scanning or autopsy. Fatal stroke was defined as death from any cause within 30 days of stroke. Severity of stroke was assessed by modified Rankin score at discharge from hospital
Non CNS Systemic Embolism (SEE), Annualized Rate of Subjects With Non-CNS SEE
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Systemic embolism was an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts), and was to be documented by angiography, surgery, scintigraphy, or autopsy.
Pulmonary Embolism (PE), Annualized Rate of Subjects With PE
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Pulmonary Embolism was generally documented by one of the following: an intraluminal filling defect in segmental or more proximal branches on spiral CT scan an intraluminal filling defect or an extension of an existing defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS) inconclusive spiral CT, pulmonary angiography or lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasound or venography.
Acute Myocardial Infarction (MI), Annualized Rate of Subjects With MI
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. a. In subjects not undergoing PCI or CABG a subject should have fulfilled at least 2 of the following: i. Typical prolonged severe chest pain or related symptoms or signs suggestive of MI. ii. Elevation of troponin or CK-MB to more than upper level of normal (ULN) or, if CK-MB was elevated at baseline, re-elevation to more than 50% increase above the previous level. iii. Development of significant Q-waves in at least 2 adjacent ECG leads. b. After percutaneous coronary intervention (within 24h). c. After coronary artery bypass grafting (within 72h). d. Silent myocardial infarction. e. Myocardial infarction could also have been demonstrated at autopsy.
Deep Vein Thrombosis, Annualized Rate of Subjects With DVT
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Deep Vein Thrombosis (DVT) was generally documented by one of the following: abnormal compression ultrasound (CUS), an intraluminal filling defect on venography.
Death, Annualized Rate of Subject Death
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Deaths were classified as being vascular (sudden/arrhythmic, pump failure death, or other vascular, including bleeding) or non-vascular, due to other specified causes (e.g., malignancy), or of unknown etiology.
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE)
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) and All Cause Death
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction, Vascular Death
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction (MI), All Cause Death and Major Bleed
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Annualized Rate of Subjects With Minor Bleeds
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Minor bleeds were clinical bleeds that did not fulfill the criteria for major bleeds. Minor bleeds were classified as associated with study medication discontinuation (temporary or permanent) or not.
Annualized Rate of Subjects With Any Bleeds (Major Plus Minor)
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Annualized Rate of Subjects With Intra-Cranial Hemorrhage (ICH)
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

Full Information

First Posted
December 12, 2008
Last Updated
June 3, 2014
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00808067
Brief Title
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
Official Title
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes
Study Type
Interventional

2. Study Status

Record Verification Date
March 2014
Overall Recruitment Status
Completed
Study Start Date
November 2008 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
December 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
The purposes of this study are: To evaluate the long-term safety of dabigatran etexilate To assess the effect of a knowledge translation intervention on patient outcomes

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
5897 (Actual)

8. Arms, Groups, and Interventions

Arm Title
dabigatran dose 1
Arm Type
Experimental
Arm Description
dabigatran high dose twice daily
Arm Title
dabigatran dose 2
Arm Type
Experimental
Arm Description
dabigatran low dose twice daily
Intervention Type
Drug
Intervention Name(s)
dabigatran dose 1
Intervention Description
dabigatran high dose twice daily
Intervention Type
Drug
Intervention Name(s)
dabigatran dose 2
Intervention Description
dabigatran low dose twice daily
Primary Outcome Measure Information:
Title
Major Bleeding, Annualized Rate of Subjects With Major Bleeds
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Major bleeding must have satisfied one or more of the following criteria: Bleeding associated with a reduction in hemoglobin of at least 20 g/L Required transfusion of at least 2 units of blood or packed cells Symptomatic bleeding in a critical area or organ: intraocular, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intra-articular, pericardial, gastrointestinal Major bleed were classified as life-threatening if they met one or more of the following criteria: Reduction in hemoglobin of at least 50 g/L Transfusion of at least 4 units of blood or packed cells Symptomatic intracranial bleeding, either subdural or intracerebral Associated with hypotension requiring use of intravenous inotropic agents Required surgical intervention to stop bleeding Resulted in death
Time Frame
up to 43 months
Secondary Outcome Measure Information:
Title
Stroke, Annualized Rate of Subjects With Stroke
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Stroke was an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke was categorized as ischemic or hemorrhagic or cause unknown based on computerized tomography (CT), magnetic resonance (MR) scanning or autopsy. Fatal stroke was defined as death from any cause within 30 days of stroke. Severity of stroke was assessed by modified Rankin score at discharge from hospital
Time Frame
up to 43 months
Title
Non CNS Systemic Embolism (SEE), Annualized Rate of Subjects With Non-CNS SEE
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Systemic embolism was an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts), and was to be documented by angiography, surgery, scintigraphy, or autopsy.
Time Frame
up to 43 months
Title
Pulmonary Embolism (PE), Annualized Rate of Subjects With PE
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Pulmonary Embolism was generally documented by one of the following: an intraluminal filling defect in segmental or more proximal branches on spiral CT scan an intraluminal filling defect or an extension of an existing defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS) inconclusive spiral CT, pulmonary angiography or lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasound or venography.
Time Frame
up to 43 months
Title
Acute Myocardial Infarction (MI), Annualized Rate of Subjects With MI
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. a. In subjects not undergoing PCI or CABG a subject should have fulfilled at least 2 of the following: i. Typical prolonged severe chest pain or related symptoms or signs suggestive of MI. ii. Elevation of troponin or CK-MB to more than upper level of normal (ULN) or, if CK-MB was elevated at baseline, re-elevation to more than 50% increase above the previous level. iii. Development of significant Q-waves in at least 2 adjacent ECG leads. b. After percutaneous coronary intervention (within 24h). c. After coronary artery bypass grafting (within 72h). d. Silent myocardial infarction. e. Myocardial infarction could also have been demonstrated at autopsy.
Time Frame
up to 43 months
Title
Deep Vein Thrombosis, Annualized Rate of Subjects With DVT
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Deep Vein Thrombosis (DVT) was generally documented by one of the following: abnormal compression ultrasound (CUS), an intraluminal filling defect on venography.
Time Frame
up to 43 months
Title
Death, Annualized Rate of Subject Death
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Deaths were classified as being vascular (sudden/arrhythmic, pump failure death, or other vascular, including bleeding) or non-vascular, due to other specified causes (e.g., malignancy), or of unknown etiology.
Time Frame
up to 43 months
Title
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE)
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Time Frame
up to 43 months
Title
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) and All Cause Death
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Time Frame
up to 43 months
Title
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction, Vascular Death
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Time Frame
up to 43 months
Title
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction (MI), All Cause Death and Major Bleed
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Time Frame
up to 43 months
Title
Annualized Rate of Subjects With Minor Bleeds
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. Minor bleeds were clinical bleeds that did not fulfill the criteria for major bleeds. Minor bleeds were classified as associated with study medication discontinuation (temporary or permanent) or not.
Time Frame
up to 43 months
Title
Annualized Rate of Subjects With Any Bleeds (Major Plus Minor)
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Time Frame
up to 43 months
Title
Annualized Rate of Subjects With Intra-Cranial Hemorrhage (ICH)
Description
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
Time Frame
up to 43 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Participation in RE-LY, requires long term anticoagulation, provides written informed consent Exclusion criteria: Permanent discontinuation of dabigatran during RE-LY
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1160.71.0046 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
1160.71.0057 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
1160.71.0211 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
1160.71.0115 Boehringer Ingelheim Investigational Site
City
Mobile
State/Province
Alabama
Country
United States
Facility Name
1160.71.0104 Boehringer Ingelheim Investigational Site
City
Lake Havasu City
State/Province
Arizona
Country
United States
Facility Name
1160.71.0185 Boehringer Ingelheim Investigational Site
City
Tucson
State/Province
Arizona
Country
United States
Facility Name
1160.71.0038 Boehringer Ingelheim Investigational Site
City
Hot Springs
State/Province
Arkansas
Country
United States
Facility Name
1160.71.0302 Boehringer Ingelheim Investigational Site
City
Jonesboro
State/Province
Arkansas
Country
United States
Facility Name
1160.71.0191 Boehringer Ingelheim Investigational Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
1160.71.0213 Boehringer Ingelheim Investigational Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
1160.71.0441 Boehringer Ingelheim Investigational Site
City
Carmichael
State/Province
California
Country
United States
Facility Name
1160.71.0333 Boehringer Ingelheim Investigational Site
City
Fullerton
State/Province
California
Country
United States
Facility Name
1160.71.0384 Boehringer Ingelheim Investigational Site
City
La Jolla
State/Province
California
Country
United States
Facility Name
1160.71.0246 Boehringer Ingelheim Investigational Site
City
Lancaster
State/Province
California
Country
United States
Facility Name
1160.71.0070 Boehringer Ingelheim Investigational Site
City
Merced
State/Province
California
Country
United States
Facility Name
1160.71.0349 Boehringer Ingelheim Investigational Site
City
Oakland
State/Province
California
Country
United States
Facility Name
1160.71.0016 Boehringer Ingelheim Investigational Site
City
Oceanside
State/Province
California
Country
United States
Facility Name
1160.71.0459 Boehringer Ingelheim Investigational Site
City
Pasadena
State/Province
California
Country
United States
Facility Name
1160.71.0270 Boehringer Ingelheim Investigational Site
City
Poway
State/Province
California
Country
United States
Facility Name
1160.71.0135 Boehringer Ingelheim Investigational Site
City
Riverside
State/Province
California
Country
United States
Facility Name
1160.71.0300 Boehringer Ingelheim Investigational Site
City
Sacramento
State/Province
California
Country
United States
Facility Name
1160.71.0284 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
1160.71.0379 Boehringer Ingelheim Investigational Site
City
Walnut Creek
State/Province
California
Country
United States
Facility Name
1160.71.0321 Boehringer Ingelheim Investigational Site
City
Colorado Springs
State/Province
Colorado
Country
United States
Facility Name
1160.71.0449 Boehringer Ingelheim Investigational Site
City
Colorado Springs
State/Province
Colorado
Country
United States
Facility Name
1160.71.0360 Boehringer Ingelheim Investigational Site
City
Denver
State/Province
Colorado
Country
United States
Facility Name
1160.71.0413 Boehringer Ingelheim Investigational Site
City
Denver
State/Province
Colorado
Country
United States
Facility Name
1160.71.0362 Boehringer Ingelheim Investigational Site
City
Fort Collins
State/Province
Colorado
Country
United States
Facility Name
1160.71.0278 Boehringer Ingelheim Investigational Site
City
Bridgeport
State/Province
Connecticut
Country
United States
Facility Name
1160.71.0482 Boehringer Ingelheim Investigational Site
City
Guilford
State/Province
Connecticut
Country
United States
Facility Name
1160.71.0382 Boehringer Ingelheim Investigational Site
City
Boynton Beach
State/Province
Florida
Country
United States
Facility Name
1160.71.0056 Boehringer Ingelheim Investigational Site
City
Brandon
State/Province
Florida
Country
United States
Facility Name
1160.71.0296 Boehringer Ingelheim Investigational Site
City
Clearwater
State/Province
Florida
Country
United States
Facility Name
1160.71.0327 Boehringer Ingelheim Investigational Site
City
Coral Springs
State/Province
Florida
Country
United States
Facility Name
1160.71.0376 Boehringer Ingelheim Investigational Site
City
Daytona Beach
State/Province
Florida
Country
United States
Facility Name
1160.71.0074 Boehringer Ingelheim Investigational Site
City
Fort Myers
State/Province
Florida
Country
United States
Facility Name
1160.71.0089 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
1160.71.0232 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
1160.71.0427 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
1160.71.0012 Boehringer Ingelheim Investigational Site
City
Lakeland
State/Province
Florida
Country
United States
Facility Name
1160.71.0034 Boehringer Ingelheim Investigational Site
City
Miami
State/Province
Florida
Country
United States
Facility Name
1160.71.0227 Boehringer Ingelheim Investigational Site
City
Orlando
State/Province
Florida
Country
United States
Facility Name
1160.71.0095 Boehringer Ingelheim Investigational Site
City
Ormond Beach
State/Province
Florida
Country
United States
Facility Name
1160.71.0037 Boehringer Ingelheim Investigational Site
City
Pensacola
State/Province
Florida
Country
United States
Facility Name
1160.71.0137 Boehringer Ingelheim Investigational Site
City
Port Charlotte
State/Province
Florida
Country
United States
Facility Name
1160.71.0417 Boehringer Ingelheim Investigational Site
City
Port Charlotte
State/Province
Florida
Country
United States
Facility Name
1160.71.0332 Boehringer Ingelheim Investigational Site
City
Rockledge
State/Province
Florida
Country
United States
Facility Name
1160.71.0385 Boehringer Ingelheim Investigational Site
City
Sarasota
State/Province
Florida
Country
United States
Facility Name
1160.71.0015 Boehringer Ingelheim Investigational Site
City
St. Petersburg
State/Province
Florida
Country
United States
Facility Name
1160.71.0339 Boehringer Ingelheim Investigational Site
City
St. Petersburg
State/Province
Florida
Country
United States
Facility Name
1160.71.0019 Boehringer Ingelheim Investigational Site
City
Vero Beach
State/Province
Florida
Country
United States
Facility Name
1160.71.0159 Boehringer Ingelheim Investigational Site
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
1160.71.0021 Boehringer Ingelheim Investigational Site
City
Augusta
State/Province
Georgia
Country
United States
Facility Name
1160.71.0161 Boehringer Ingelheim Investigational Site
City
Conyers
State/Province
Georgia
Country
United States
Facility Name
1160.71.0218 Boehringer Ingelheim Investigational Site
City
Cicero
State/Province
Illinois
Country
United States
Facility Name
1160.71.0438 Boehringer Ingelheim Investigational Site
City
Maywood
State/Province
Illinois
Country
United States
Facility Name
1160.71.0331 Boehringer Ingelheim Investigational Site
City
Melrose Park
State/Province
Illinois
Country
United States
Facility Name
1160.71.0364 Boehringer Ingelheim Investigational Site
City
Normal
State/Province
Illinois
Country
United States
Facility Name
1160.71.0109 Boehringer Ingelheim Investigational Site
City
North Chicago
State/Province
Illinois
Country
United States
Facility Name
1160.71.0152 Boehringer Ingelheim Investigational Site
City
Oak Lawn
State/Province
Illinois
Country
United States
Facility Name
1160.71.0198 Boehringer Ingelheim Investigational Site
City
Rockford
State/Province
Illinois
Country
United States
Facility Name
1160.71.0433 Boehringer Ingelheim Investigational Site
City
Winfield
State/Province
Illinois
Country
United States
Facility Name
1160.71.0377 Boehringer Ingelheim Investigational Site
City
Fort Wayne
State/Province
Indiana
Country
United States
Facility Name
1160.71.0288 Boehringer Ingelheim Investigational Site
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
1160.71.0352 Boehringer Ingelheim Investigational Site
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
1160.71.0436 Boehringer Ingelheim Investigational Site
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
1160.71.0235 Boehringer Ingelheim Investigational Site
City
South Bend
State/Province
Indiana
Country
United States
Facility Name
1160.71.0268 Boehringer Ingelheim Investigational Site
City
Dubuque
State/Province
Iowa
Country
United States
Facility Name
1160.71.0001 Boehringer Ingelheim Investigational Site
City
West Des Moines
State/Province
Iowa
Country
United States
Facility Name
1160.71.0357 Boehringer Ingelheim Investigational Site
City
West Des Moines
State/Province
Iowa
Country
United States
Facility Name
1160.71.0422 Boehringer Ingelheim Investigational Site
City
Lexington
State/Province
Kentucky
Country
United States
Facility Name
1160.71.0178 Boehringer Ingelheim Investigational Site
City
Louisville
State/Province
Kentucky
Country
United States
Facility Name
1160.71.0397 Boehringer Ingelheim Investigational Site
City
Louisville
State/Province
Kentucky
Country
United States
Facility Name
1160.71.0310 Boehringer Ingelheim Investigational Site
City
Owensboro
State/Province
Kentucky
Country
United States
Facility Name
1160.71.0144 Boehringer Ingelheim Investigational Site
City
Baton Rouge
State/Province
Louisiana
Country
United States
Facility Name
1160.71.0018 Boehringer Ingelheim Investigational Site
City
Lafayette
State/Province
Louisiana
Country
United States
Facility Name
1160.71.0132 Boehringer Ingelheim Investigational Site
City
New Iberia
State/Province
Louisiana
Country
United States
Facility Name
1160.71.0096 Boehringer Ingelheim Investigational Site
City
Auburn
State/Province
Maine
Country
United States
Facility Name
1160.71.0114 Boehringer Ingelheim Investigational Site
City
Annapolis
State/Province
Maryland
Country
United States
Facility Name
1160.71.0023 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1160.71.0047 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1160.71.0079 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1160.71.0186 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1160.71.0194 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1160.71.0255 Boehringer Ingelheim Investigational Site
City
Bel Air
State/Province
Maryland
Country
United States
Facility Name
1160.71.0398 Boehringer Ingelheim Investigational Site
City
Columbia
State/Province
Maryland
Country
United States
Facility Name
1160.71.0177 Boehringer Ingelheim Investigational Site
City
Rockville
State/Province
Maryland
Country
United States
Facility Name
1160.71.0073 Boehringer Ingelheim Investigational Site
City
Salisbury
State/Province
Maryland
Country
United States
Facility Name
1160.71.0207 Boehringer Ingelheim Investigational Site
City
Salisbury
State/Province
Maryland
Country
United States
Facility Name
1160.71.0196 Boehringer Ingelheim Investigational Site
City
Takoma Park
State/Province
Maryland
Country
United States
Facility Name
1160.71.0187 Boehringer Ingelheim Investigational Site
City
Towson
State/Province
Maryland
Country
United States
Facility Name
1160.71.0052 Boehringer Ingelheim Investigational Site
City
Westminster
State/Province
Maryland
Country
United States
Facility Name
1160.71.0443 Boehringer Ingelheim Investigational Site
City
Haverhill
State/Province
Massachusetts
Country
United States
Facility Name
1160.71.0452 Boehringer Ingelheim Investigational Site
City
Haverhill
State/Province
Massachusetts
Country
United States
Facility Name
1160.71.0029 Boehringer Ingelheim Investigational Site
City
Natick
State/Province
Massachusetts
Country
United States
Facility Name
1160.71.0003 Boehringer Ingelheim Investigational Site
City
North Dartmouth
State/Province
Massachusetts
Country
United States
Facility Name
1160.71.0308 Boehringer Ingelheim Investigational Site
City
Worcester
State/Province
Massachusetts
Country
United States
Facility Name
1160.71.0154 Boehringer Ingelheim Investigational Site
City
Grand Blanc
State/Province
Michigan
Country
United States
Facility Name
1160.71.0205 Boehringer Ingelheim Investigational Site
City
Lapeer
State/Province
Michigan
Country
United States
Facility Name
1160.71.0279 Boehringer Ingelheim Investigational Site
City
Muskegon
State/Province
Michigan
Country
United States
Facility Name
1160.71.0445 Boehringer Ingelheim Investigational Site
City
Petoskey
State/Province
Michigan
Country
United States
Facility Name
1160.71.0274 Boehringer Ingelheim Investigational Site
City
Rochester Hills
State/Province
Michigan
Country
United States
Facility Name
1160.71.0165 Boehringer Ingelheim Investigational Site
City
Saginaw
State/Province
Michigan
Country
United States
Facility Name
1160.71.0020 Boehringer Ingelheim Investigational Site
City
Troy
State/Province
Michigan
Country
United States
Facility Name
1160.71.0188 Boehringer Ingelheim Investigational Site
City
Ypsilanti
State/Province
Michigan
Country
United States
Facility Name
1160.71.0202 Boehringer Ingelheim Investigational Site
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
1160.71.0101 Boehringer Ingelheim Investigational Site
City
St. Paul
State/Province
Minnesota
Country
United States
Facility Name
1160.71.0086 Boehringer Ingelheim Investigational Site
City
Gulfport
State/Province
Mississippi
Country
United States
Facility Name
1160.71.0119 Boehringer Ingelheim Investigational Site
City
Tupelo
State/Province
Mississippi
Country
United States
Facility Name
1160.71.0055 Boehringer Ingelheim Investigational Site
City
Columbia
State/Province
Missouri
Country
United States
Facility Name
1160.71.0257 Boehringer Ingelheim Investigational Site
City
Kansas City
State/Province
Missouri
Country
United States
Facility Name
1160.71.0336 Boehringer Ingelheim Investigational Site
City
St. Charles
State/Province
Missouri
Country
United States
Facility Name
1160.71.0249 Boehringer Ingelheim Investigational Site
City
St. Louis
State/Province
Missouri
Country
United States
Facility Name
1160.71.0027 Boehringer Ingelheim Investigational Site
City
Kalispell
State/Province
Montana
Country
United States
Facility Name
1160.71.0110 Boehringer Ingelheim Investigational Site
City
Omaha
State/Province
Nebraska
Country
United States
Facility Name
1160.71.0346 Boehringer Ingelheim Investigational Site
City
Henderson
State/Province
Nevada
Country
United States
Facility Name
1160.71.0430 Boehringer Ingelheim Investigational Site
City
Las Vegas
State/Province
Nevada
Country
United States
Facility Name
1160.71.0142 Boehringer Ingelheim Investigational Site
City
Browns Mills
State/Province
New Jersey
Country
United States
Facility Name
1160.71.0221 Boehringer Ingelheim Investigational Site
City
Cherry Hill
State/Province
New Jersey
Country
United States
Facility Name
1160.71.0248 Boehringer Ingelheim Investigational Site
City
Flemington
State/Province
New Jersey
Country
United States
Facility Name
1160.71.0478 Boehringer Ingelheim Investigational Site
City
Oakland
State/Province
New Jersey
Country
United States
Facility Name
1160.71.0392 Boehringer Ingelheim Investigational Site
City
Ocean
State/Province
New Jersey
Country
United States
Facility Name
1160.71.0254 Boehringer Ingelheim Investigational Site
City
Westwood
State/Province
New Jersey
Country
United States
Facility Name
1160.71.0472 Boehringer Ingelheim Investigational Site
City
Woodland Park
State/Province
New Jersey
Country
United States
Facility Name
1160.71.0476 Boehringer Ingelheim Investigational Site
City
Albany
State/Province
New York
Country
United States
Facility Name
1160.71.0113 Boehringer Ingelheim Investigational Site
City
Bronx
State/Province
New York
Country
United States
Facility Name
1160.71.0281 Boehringer Ingelheim Investigational Site
City
Bronx
State/Province
New York
Country
United States
Facility Name
1160.71.0044 Boehringer Ingelheim Investigational Site
City
Cortlandt Manor
State/Province
New York
Country
United States
Facility Name
1160.71.0229 Boehringer Ingelheim Investigational Site
City
Mineola
State/Province
New York
Country
United States
Facility Name
1160.71.0451 Boehringer Ingelheim Investigational Site
City
Mineola
State/Province
New York
Country
United States
Facility Name
1160.71.0183 Boehringer Ingelheim Investigational Site
City
New Rochelle
State/Province
New York
Country
United States
Facility Name
1160.71.0210 Boehringer Ingelheim Investigational Site
City
Northport
State/Province
New York
Country
United States
Facility Name
1160.71.0075 Boehringer Ingelheim Investigational Site
City
Poughkeepsie
State/Province
New York
Country
United States
Facility Name
1160.71.0414 Boehringer Ingelheim Investigational Site
City
Troy
State/Province
New York
Country
United States
Facility Name
1160.71.0356 Boehringer Ingelheim Investigational Site
City
Watertown
State/Province
New York
Country
United States
Facility Name
1160.71.0064 Boehringer Ingelheim Investigational Site
City
Yonkers
State/Province
New York
Country
United States
Facility Name
1160.71.0353 Boehringer Ingelheim Investigational Site
City
Asheville
State/Province
North Carolina
Country
United States
Facility Name
1160.71.0080 Boehringer Ingelheim Investigational Site
City
Charlotte
State/Province
North Carolina
Country
United States
Facility Name
1160.71.0350 Boehringer Ingelheim Investigational Site
City
Gastonia
State/Province
North Carolina
Country
United States
Facility Name
1160.71.0173 Boehringer Ingelheim Investigational Site
City
High Point
State/Province
North Carolina
Country
United States
Facility Name
1160.71.0006 Boehringer Ingelheim Investigational Site
City
Pinehurst
State/Province
North Carolina
Country
United States
Facility Name
1160.71.0002 Boehringer Ingelheim Investigational Site
City
Statesville
State/Province
North Carolina
Country
United States
Facility Name
1160.71.0069 Boehringer Ingelheim Investigational Site
City
Statesville
State/Province
North Carolina
Country
United States
Facility Name
1160.71.0102 Boehringer Ingelheim Investigational Site
City
Grand Forks
State/Province
North Dakota
Country
United States
Facility Name
1160.71.0222 Boehringer Ingelheim Investigational Site
City
Jamestown
State/Province
North Dakota
Country
United States
Facility Name
1160.71.0203 Boehringer Ingelheim Investigational Site
City
Akron
State/Province
Ohio
Country
United States
Facility Name
1160.71.0434 Boehringer Ingelheim Investigational Site
City
Canal Fulton
State/Province
Ohio
Country
United States
Facility Name
1160.71.0402 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
1160.71.0426 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
1160.71.0479 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
1160.71.0263 Boehringer Ingelheim Investigational Site
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
1160.71.0480 Boehringer Ingelheim Investigational Site
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
1160.71.0267 Boehringer Ingelheim Investigational Site
City
Columbus
State/Province
Ohio
Country
United States
Facility Name
1160.71.0035 Boehringer Ingelheim Investigational Site
City
Dayton
State/Province
Ohio
Country
United States
Facility Name
1160.71.0150 Boehringer Ingelheim Investigational Site
City
Fairview Park
State/Province
Ohio
Country
United States
Facility Name
1160.71.0201 Boehringer Ingelheim Investigational Site
City
Kettering
State/Province
Ohio
Country
United States
Facility Name
1160.71.0223 Boehringer Ingelheim Investigational Site
City
Lorain
State/Province
Ohio
Country
United States
Facility Name
1160.71.0214 Boehringer Ingelheim Investigational Site
City
Lyndhurst
State/Province
Ohio
Country
United States
Facility Name
1160.71.0275 Boehringer Ingelheim Investigational Site
City
Sandusky
State/Province
Ohio
Country
United States
Facility Name
1160.71.0103 Boehringer Ingelheim Investigational Site
City
Westlake
State/Province
Ohio
Country
United States
Facility Name
1160.71.0435 Boehringer Ingelheim Investigational Site
City
Tulsa
State/Province
Oklahoma
Country
United States
Facility Name
1160.71.0139 Boehringer Ingelheim Investigational Site
City
Corvallis
State/Province
Oregon
Country
United States
Facility Name
1160.71.0325 Boehringer Ingelheim Investigational Site
City
Eugene
State/Province
Oregon
Country
United States
Facility Name
1160.71.0133 Boehringer Ingelheim Investigational Site
City
Springfield
State/Province
Oregon
Country
United States
Facility Name
1160.71.0301 Boehringer Ingelheim Investigational Site
City
Allentown
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0295 Boehringer Ingelheim Investigational Site
City
Camp Hill
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0294 Boehringer Ingelheim Investigational Site
City
Hershey
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0369 Boehringer Ingelheim Investigational Site
City
Jenkintown
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0431 Boehringer Ingelheim Investigational Site
City
Lancaster
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0168 Boehringer Ingelheim Investigational Site
City
Langhorne
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0293 Boehringer Ingelheim Investigational Site
City
Meadowbrook
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0394 Boehringer Ingelheim Investigational Site
City
Norristown
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0466 Boehringer Ingelheim Investigational Site
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0208 Boehringer Ingelheim Investigational Site
City
Sellersville
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0465 Boehringer Ingelheim Investigational Site
City
Uniontown
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0032 Boehringer Ingelheim Investigational Site
City
Wynnewood
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0067 Boehringer Ingelheim Investigational Site
City
Wyomissing
State/Province
Pennsylvania
Country
United States
Facility Name
1160.71.0007 Boehringer Ingelheim Investigational Site
City
Beaufort
State/Province
South Carolina
Country
United States
Facility Name
1160.71.0383 Boehringer Ingelheim Investigational Site
City
Charleston
State/Province
South Carolina
Country
United States
Facility Name
1160.71.0313 Boehringer Ingelheim Investigational Site
City
Greenville
State/Province
South Carolina
Country
United States
Facility Name
1160.71.0166 Boehringer Ingelheim Investigational Site
City
Spartanburg
State/Province
South Carolina
Country
United States
Facility Name
1160.71.0008 Boehringer Ingelheim Investigational Site
City
Summerville
State/Province
South Carolina
Country
United States
Facility Name
1160.71.0084 Boehringer Ingelheim Investigational Site
City
Chattanooga
State/Province
Tennessee
Country
United States
Facility Name
1160.71.0474 Boehringer Ingelheim Investigational Site
City
Clinton
State/Province
Tennessee
Country
United States
Facility Name
1160.71.0062 Boehringer Ingelheim Investigational Site
City
Germantown
State/Province
Tennessee
Country
United States
Facility Name
1160.71.0370 Boehringer Ingelheim Investigational Site
City
Johnson City
State/Province
Tennessee
Country
United States
Facility Name
1160.71.0395 Boehringer Ingelheim Investigational Site
City
Nashville
State/Province
Tennessee
Country
United States
Facility Name
1160.71.0129 Boehringer Ingelheim Investigational Site
City
Austin
State/Province
Texas
Country
United States
Facility Name
1160.71.0410 Boehringer Ingelheim Investigational Site
City
Austin
State/Province
Texas
Country
United States
Facility Name
1160.71.0156 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
1160.71.0315 Boehringer Ingelheim Investigational Site
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
1160.71.0447 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
1160.71.0483 Boehringer Ingelheim Investigational Site
City
Killeen
State/Province
Texas
Country
United States
Facility Name
1160.71.0335 Boehringer Ingelheim Investigational Site
City
Lubbock
State/Province
Texas
Country
United States
Facility Name
1160.71.0269 Boehringer Ingelheim Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
1160.71.0307 Boehringer Ingelheim Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
1160.71.0285 Boehringer Ingelheim Investigational Site
City
San Marcos
State/Province
Texas
Country
United States
Facility Name
1160.71.0367 Boehringer Ingelheim Investigational Site
City
Tyler
State/Province
Texas
Country
United States
Facility Name
1160.71.0453 Boehringer Ingelheim Investigational Site
City
Charlottesville
State/Province
Virginia
Country
United States
Facility Name
1160.71.0053 Boehringer Ingelheim Investigational Site
City
Chesapeake
State/Province
Virginia
Country
United States
Facility Name
1160.71.0428 Boehringer Ingelheim Investigational Site
City
Fredericksburg
State/Province
Virginia
Country
United States
Facility Name
1160.71.0311 Boehringer Ingelheim Investigational Site
City
Harrisonburg
State/Province
Virginia
Country
United States
Facility Name
1160.71.0292 Boehringer Ingelheim Investigational Site
City
Newport News
State/Province
Virginia
Country
United States
Facility Name
1160.71.0220 Boehringer Ingelheim Investigational Site
City
Salem
State/Province
Virginia
Country
United States
Facility Name
1160.71.0224 Boehringer Ingelheim Investigational Site
City
Suffolk
State/Province
Virginia
Country
United States
Facility Name
1160.71.0317 Boehringer Ingelheim Investigational Site
City
Winchester
State/Province
Virginia
Country
United States
Facility Name
1160.71.0050 Boehringer Ingelheim Investigational Site
City
Bellingham
State/Province
Washington
Country
United States
Facility Name
1160.71.0040 Boehringer Ingelheim Investigational Site
City
Burien
State/Province
Washington
Country
United States
Facility Name
1160.71.0250 Boehringer Ingelheim Investigational Site
City
Spokane
State/Province
Washington
Country
United States
Facility Name
1160.71.0256 Boehringer Ingelheim Investigational Site
City
Tacoma
State/Province
Washington
Country
United States
Facility Name
1160.71.0024 Boehringer Ingelheim Investigational Site
City
Wenatchee
State/Province
Washington
Country
United States
Facility Name
1160.71.0169 Boehringer Ingelheim Investigational Site
City
Clarksburg
State/Province
West Virginia
Country
United States
Facility Name
1160.71.0365 Boehringer Ingelheim Investigational Site
City
Huntington
State/Province
West Virginia
Country
United States
Facility Name
1160.71.0099 Boehringer Ingelheim Investigational Site
City
Madison
State/Province
Wisconsin
Country
United States
Facility Name
1160.71.0072 Boehringer Ingelheim Investigational Site
City
Milwaukee
State/Province
Wisconsin
Country
United States
Facility Name
1160.71.0461 Boehringer Ingelheim Investigational Site
City
Milwaukee
State/Province
Wisconsin
Country
United States
Facility Name
1160.71.0508 Boehringer Ingelheim Investigational Site
City
Coffs Harbour
State/Province
New South Wales
Country
Australia
Facility Name
1160.71.0510 Boehringer Ingelheim Investigational Site
City
Gosford
State/Province
New South Wales
Country
Australia
Facility Name
1160.71.0506 Boehringer Ingelheim Investigational Site
City
Milton
State/Province
Queensland
Country
Australia
Facility Name
1160.71.0509 Boehringer Ingelheim Investigational Site
City
Ashford
State/Province
South Australia
Country
Australia
Facility Name
1160.71.0507 Boehringer Ingelheim Investigational Site
City
Launceston
State/Province
Tasmania
Country
Australia
Facility Name
1160.71.0504 Boehringer Ingelheim Investigational Site
City
Box Hill
State/Province
Victoria
Country
Australia
Facility Name
1160.71.0501 Boehringer Ingelheim Investigational Site
City
Geelong
State/Province
Victoria
Country
Australia
Facility Name
1160.71.0543 Boehringer Ingelheim Investigational Site
City
Graz
Country
Austria
Facility Name
1160.71.0549 Boehringer Ingelheim Investigational Site
City
Linz
Country
Austria
Facility Name
1160.71.0541 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.71.0542 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.71.0545 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.71.0547 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.71.0548 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1160.71.0550 Boehringer Ingelheim Investigational Site
City
Wr. Neustadt
Country
Austria
Facility Name
1160.71.0564 Boehringer Ingelheim Investigational Site
City
Aalst
Country
Belgium
Facility Name
1160.71.0572 Boehringer Ingelheim Investigational Site
City
Brasschaat
Country
Belgium
Facility Name
1160.71.0571 Boehringer Ingelheim Investigational Site
City
Brussel
Country
Belgium
Facility Name
1160.71.0581 Boehringer Ingelheim Investigational Site
City
Bruxelles
Country
Belgium
Facility Name
1160.71.0585 Boehringer Ingelheim Investigational Site
City
Bruxelles
Country
Belgium
Facility Name
1160.71.0563 Boehringer Ingelheim Investigational Site
City
Edegem
Country
Belgium
Facility Name
1160.71.0578 Boehringer Ingelheim Investigational Site
City
Genk
Country
Belgium
Facility Name
1160.71.0587 Boehringer Ingelheim Investigational Site
City
Genk
Country
Belgium
Facility Name
1160.71.0574 Boehringer Ingelheim Investigational Site
City
Gent
Country
Belgium
Facility Name
1160.71.0588 Boehringer Ingelheim Investigational Site
City
Gilly
Country
Belgium
Facility Name
1160.71.0568 Boehringer Ingelheim Investigational Site
City
Hasselt
Country
Belgium
Facility Name
1160.71.0561 Boehringer Ingelheim Investigational Site
City
Leuven
Country
Belgium
Facility Name
1160.71.0579 Boehringer Ingelheim Investigational Site
City
Liège
Country
Belgium
Facility Name
1160.71.0567 Boehringer Ingelheim Investigational Site
City
Oostende
Country
Belgium
Facility Name
1160.71.0570 Boehringer Ingelheim Investigational Site
City
Roeselare
Country
Belgium
Facility Name
1160.71.0566 Boehringer Ingelheim Investigational Site
City
Tienen
Country
Belgium
Facility Name
1160.71.0562 Boehringer Ingelheim Investigational Site
City
Turnhout
Country
Belgium
Facility Name
1160.71.0644 Boehringer Ingelheim Investigational Site
City
Campinas
Country
Brazil
Facility Name
1160.71.0650 Boehringer Ingelheim Investigational Site
City
Curitiba
Country
Brazil
Facility Name
1160.71.0651 Boehringer Ingelheim Investigational Site
City
Curitiba
Country
Brazil
Facility Name
1160.71.0652 Boehringer Ingelheim Investigational Site
City
Goiania
Country
Brazil
Facility Name
1160.71.0646 Boehringer Ingelheim Investigational Site
City
Sao Jose do Riio Preto
Country
Brazil
Facility Name
1160.71.0647 Boehringer Ingelheim Investigational Site
City
São José do Rio Preto
Country
Brazil
Facility Name
1160.71.0643 Boehringer Ingelheim Investigational Site
City
São Paulo
Country
Brazil
Facility Name
1160.71.0620 Boehringer Ingelheim Investigational Site
City
Pleven
Country
Bulgaria
Facility Name
1160.71.0611 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.71.0612 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.71.0615 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.71.0617 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.71.0618 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.71.0625 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1160.71.0694 Boehringer Ingelheim Investigational Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
1160.71.0696 Boehringer Ingelheim Investigational Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
1160.71.0680 Boehringer Ingelheim Investigational Site
City
Coquitlam
State/Province
British Columbia
Country
Canada
Facility Name
1160.71.0712 Boehringer Ingelheim Investigational Site
City
Coquitlam
State/Province
British Columbia
Country
Canada
Facility Name
1160.71.0706 Boehringer Ingelheim Investigational Site
City
Kelowna
State/Province
British Columbia
Country
Canada
Facility Name
1160.71.0725 Boehringer Ingelheim Investigational Site
City
Nanaimo
State/Province
British Columbia
Country
Canada
Facility Name
1160.71.0691 Boehringer Ingelheim Investigational Site
City
New Westminster
State/Province
British Columbia
Country
Canada
Facility Name
1160.71.0714 Boehringer Ingelheim Investigational Site
City
Victoria
State/Province
British Columbia
Country
Canada
Facility Name
1160.71.0701 Boehringer Ingelheim Investigational Site
City
Portage la Prairie
State/Province
Manitoba
Country
Canada
Facility Name
1160.71.0703 Boehringer Ingelheim Investigational Site
City
Halifax
State/Province
Nova Scotia
Country
Canada
Facility Name
1160.71.0674 Boehringer Ingelheim Investigational Site
City
Burlington
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0702 Boehringer Ingelheim Investigational Site
City
Cambridge
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0720 Boehringer Ingelheim Investigational Site
City
Cambridge
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0692 Boehringer Ingelheim Investigational Site
City
Grimsby
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0697 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0710 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0719 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0721 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0708 Boehringer Ingelheim Investigational Site
City
Mississauga
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0688 Boehringer Ingelheim Investigational Site
City
Newmarket
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0672 Boehringer Ingelheim Investigational Site
City
Oshawa
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0687 Boehringer Ingelheim Investigational Site
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0679 Boehringer Ingelheim Investigational Site
City
Scarborough
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0723 Boehringer Ingelheim Investigational Site
City
Scarborough
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0715 Boehringer Ingelheim Investigational Site
City
Sudbury
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0690 Boehringer Ingelheim Investigational Site
City
Thunder Bay
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0684 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0718 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0686 Boehringer Ingelheim Investigational Site
City
Windsor
State/Province
Ontario
Country
Canada
Facility Name
1160.71.0683 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1160.71.0705 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1160.71.0709 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1160.71.0716 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1160.71.0717 Boehringer Ingelheim Investigational Site
City
Quebec City
State/Province
Quebec
Country
Canada
Facility Name
1160.71.0699 Boehringer Ingelheim Investigational Site
City
St. Charles-Borromee
State/Province
Quebec
Country
Canada
Facility Name
1160.71.0713 Boehringer Ingelheim Investigational Site
City
St. George-de-Beauce
State/Province
Quebec
Country
Canada
Facility Name
1160.71.0675 Boehringer Ingelheim Investigational Site
City
St. Hyacinthe
State/Province
Quebec
Country
Canada
Facility Name
1160.71.0673 Boehringer Ingelheim Investigational Site
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
1160.71.0678 Boehringer Ingelheim Investigational Site
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
1160.71.0700 Boehringer Ingelheim Investigational Site
City
Quebec
Country
Canada
Facility Name
1160.71.0771 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1160.71.0772 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1160.71.0773 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1160.71.0774 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1160.71.0776 Boehringer Ingelheim Investigational Site
City
Haerbin
Country
China
Facility Name
1160.71.0784 Boehringer Ingelheim Investigational Site
City
Hangzhou
Country
China
Facility Name
1160.71.0778 Boehringer Ingelheim Investigational Site
City
QingDao
Country
China
Facility Name
1160.71.0781 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
1160.71.0782 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
1160.71.0777 Boehringer Ingelheim Investigational Site
City
Shenyang
Country
China
Facility Name
1160.71.0780 Boehringer Ingelheim Investigational Site
City
Shijiazhuang
Country
China
Facility Name
1160.71.0816 Boehringer Ingelheim Investigational Site
City
Modrice
Country
Czech Republic
Facility Name
1160.71.0820 Boehringer Ingelheim Investigational Site
City
Ostrava 1
Country
Czech Republic
Facility Name
1160.71.0818 Boehringer Ingelheim Investigational Site
City
Pardubice
Country
Czech Republic
Facility Name
1160.71.0814 Boehringer Ingelheim Investigational Site
City
Plzen-Bory
Country
Czech Republic
Facility Name
1160.71.0811 Boehringer Ingelheim Investigational Site
City
Praha 5
Country
Czech Republic
Facility Name
1160.71.0812 Boehringer Ingelheim Investigational Site
City
Praha 6
Country
Czech Republic
Facility Name
1160.71.0813 Boehringer Ingelheim Investigational Site
City
Praha 9
Country
Czech Republic
Facility Name
1160.71.0817 Boehringer Ingelheim Investigational Site
City
Pribram
Country
Czech Republic
Facility Name
1160.71.0819 Boehringer Ingelheim Investigational Site
City
Usti nad Orlici
Country
Czech Republic
Facility Name
1160.71.0837 Boehringer Ingelheim Investigational Site
City
Aalborg
Country
Denmark
Facility Name
1160.71.0835 Boehringer Ingelheim Investigational Site
City
Aarhus C
Country
Denmark
Facility Name
1160.71.0838 Boehringer Ingelheim Investigational Site
City
Frederikssund
Country
Denmark
Facility Name
1160.71.0833 Boehringer Ingelheim Investigational Site
City
Helsingør
Country
Denmark
Facility Name
1160.71.0834 Boehringer Ingelheim Investigational Site
City
Herlev
Country
Denmark
Facility Name
1160.71.0841 Boehringer Ingelheim Investigational Site
City
Horsens
Country
Denmark
Facility Name
1160.71.0832 Boehringer Ingelheim Investigational Site
City
Hvidovre
Country
Denmark
Facility Name
1160.71.0840 Boehringer Ingelheim Investigational Site
City
Køge
Country
Denmark
Facility Name
1160.71.0831 Boehringer Ingelheim Investigational Site
City
Odense
Country
Denmark
Facility Name
1160.71.0839 Boehringer Ingelheim Investigational Site
City
Roskilde
Country
Denmark
Facility Name
1160.71.0836 Boehringer Ingelheim Investigational Site
City
Svendborg
Country
Denmark
Facility Name
1160.71.0851 Boehringer Ingelheim Investigational Site
City
Helsinki
Country
Finland
Facility Name
1160.71.0859 Boehringer Ingelheim Investigational Site
City
Jyväskylä
Country
Finland
Facility Name
1160.71.0854 Boehringer Ingelheim Investigational Site
City
Oulu
Country
Finland
Facility Name
1160.71.0858 Boehringer Ingelheim Investigational Site
City
Pori
Country
Finland
Facility Name
1160.71.0852 Boehringer Ingelheim Investigational Site
City
Tampere
Country
Finland
Facility Name
1160.71.0853 Boehringer Ingelheim Investigational Site
City
Turku
Country
Finland
Facility Name
1160.71.875A Boehringer Ingelheim Investigational Site
City
ABBEVILLE cedex
Country
France
Facility Name
1160.71.882D Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.71.882G Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
1160.71.879F Boehringer Ingelheim Investigational Site
City
Besle Sur Vilaine
Country
France
Facility Name
1160.71.887A Boehringer Ingelheim Investigational Site
City
Cholet
Country
France
Facility Name
1160.71.882K Boehringer Ingelheim Investigational Site
City
Château Gontier
Country
France
Facility Name
1160.71.879C Boehringer Ingelheim Investigational Site
City
Derval
Country
France
Facility Name
1160.71.882H Boehringer Ingelheim Investigational Site
City
Feneu
Country
France
Facility Name
1160.71.888A Boehringer Ingelheim Investigational Site
City
GRENOBLE Cédex 9
Country
France
Facility Name
1160.71.879B Boehringer Ingelheim Investigational Site
City
La Chapelle sur Erdre
Country
France
Facility Name
1160.71.874A Boehringer Ingelheim Investigational Site
City
Langres
Country
France
Facility Name
1160.71.884A Boehringer Ingelheim Investigational Site
City
Laval
Country
France
Facility Name
1160.71.880B Boehringer Ingelheim Investigational Site
City
Le Mesnil en Valée
Country
France
Facility Name
1160.71.880A Boehringer Ingelheim Investigational Site
City
Murs Erigne
Country
France
Facility Name
1160.71.879A Boehringer Ingelheim Investigational Site
City
Nantes
Country
France
Facility Name
1160.71.879H Boehringer Ingelheim Investigational Site
City
Nantes
Country
France
Facility Name
1160.71.879S Boehringer Ingelheim Investigational Site
City
Nantes
Country
France
Facility Name
1160.71.880J Boehringer Ingelheim Investigational Site
City
Parcay les Pins
Country
France
Facility Name
1160.71.871A Boehringer Ingelheim Investigational Site
City
Paris
Country
France
Facility Name
1160.71.879E Boehringer Ingelheim Investigational Site
City
Saint Aubin Des Chateaux
Country
France
Facility Name
1160.71.880D Boehringer Ingelheim Investigational Site
City
Segre
Country
France
Facility Name
1160.71.882A Boehringer Ingelheim Investigational Site
City
Tierce
Country
France
Facility Name
1160.71.882B Boehringer Ingelheim Investigational Site
City
Tierce
Country
France
Facility Name
1160.71.882C Boehringer Ingelheim Investigational Site
City
Tierce
Country
France
Facility Name
1160.71.879G Boehringer Ingelheim Investigational Site
City
Vieillevigne
Country
France
Facility Name
1160.71.880E Boehringer Ingelheim Investigational Site
City
Vihiers
Country
France
Facility Name
1160.71.0932 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1160.71.0948 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1160.71.0962 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1160.71.0940 Boehringer Ingelheim Investigational Site
City
Bochum
Country
Germany
Facility Name
1160.71.0972 Boehringer Ingelheim Investigational Site
City
Dortmund
Country
Germany
Facility Name
1160.71.0934 Boehringer Ingelheim Investigational Site
City
Essen
Country
Germany
Facility Name
1160.71.0931 Boehringer Ingelheim Investigational Site
City
Frankfurt am Main
Country
Germany
Facility Name
1160.71.0943 Boehringer Ingelheim Investigational Site
City
Heidelberg
Country
Germany
Facility Name
1160.71.0963 Boehringer Ingelheim Investigational Site
City
Köln
Country
Germany
Facility Name
1160.71.0946 Boehringer Ingelheim Investigational Site
City
Lahr
Country
Germany
Facility Name
1160.71.0944 Boehringer Ingelheim Investigational Site
City
Limburg
Country
Germany
Facility Name
1160.71.0951 Boehringer Ingelheim Investigational Site
City
Mainz
Country
Germany
Facility Name
1160.71.0933 Boehringer Ingelheim Investigational Site
City
Mannheim
Country
Germany
Facility Name
1160.71.0945 Boehringer Ingelheim Investigational Site
City
Mannheim
Country
Germany
Facility Name
1160.71.0970 Boehringer Ingelheim Investigational Site
City
Mannheim
Country
Germany
Facility Name
1160.71.0937 Boehringer Ingelheim Investigational Site
City
Witten
Country
Germany
Facility Name
1160.71.0966 Boehringer Ingelheim Investigational Site
City
Wuppertal
Country
Germany
Facility Name
1160.71.0901 Boehringer Ingelheim Investigational Site
City
Athens
Country
Greece
Facility Name
1160.71.0914 Boehringer Ingelheim Investigational Site
City
Kalamaria-Thessaloniki
Country
Greece
Facility Name
1160.71.0904 Boehringer Ingelheim Investigational Site
City
Larissa
Country
Greece
Facility Name
1160.71.0910 Boehringer Ingelheim Investigational Site
City
Thiva
Country
Greece
Facility Name
1160.71.0903 Boehringer Ingelheim Investigational Site
City
Trikala
Country
Greece
Facility Name
1160.71.0905 Boehringer Ingelheim Investigational Site
City
Voula - Athens
Country
Greece
Facility Name
1160.71.1003 Boehringer Ingelheim Investigational Site
City
Kowloon
Country
Hong Kong
Facility Name
1160.71.1004 Boehringer Ingelheim Investigational Site
City
Kowloon
Country
Hong Kong
Facility Name
1160.71.1011 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.71.1012 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.71.1013 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.71.1014 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.71.1015 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.71.1016 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1160.71.1020 Boehringer Ingelheim Investigational Site
City
Gyongyos
Country
Hungary
Facility Name
1160.71.1017 Boehringer Ingelheim Investigational Site
City
Komarom
Country
Hungary
Facility Name
1160.71.1018 Boehringer Ingelheim Investigational Site
City
Pecs
Country
Hungary
Facility Name
1160.71.1056 Boehringer Ingelheim Investigational Site
City
Ahmedabad-52
Country
India
Facility Name
1160.71.1057 Boehringer Ingelheim Investigational Site
City
Ahmedabad
Country
India
Facility Name
1160.71.1065 Boehringer Ingelheim Investigational Site
City
Bangalore
Country
India
Facility Name
1160.71.1062 Boehringer Ingelheim Investigational Site
City
Hyderabad
Country
India
Facility Name
1160.71.1073 Boehringer Ingelheim Investigational Site
City
Jaipur, Rajasthan
Country
India
Facility Name
1160.71.1067 Boehringer Ingelheim Investigational Site
City
Kerala
Country
India
Facility Name
1160.71.1068 Boehringer Ingelheim Investigational Site
City
Kottayam
Country
India
Facility Name
1160.71.1055 Boehringer Ingelheim Investigational Site
City
Lucknow, Uttar Pradesh
Country
India
Facility Name
1160.71.1051 Boehringer Ingelheim Investigational Site
City
Ludhiana
Country
India
Facility Name
1160.71.1072 Boehringer Ingelheim Investigational Site
City
Mysore
Country
India
Facility Name
1160.71.1059 Boehringer Ingelheim Investigational Site
City
Nagpur-12
Country
India
Facility Name
1160.71.1052 Boehringer Ingelheim Investigational Site
City
New Delhi
Country
India
Facility Name
1160.71.1070 Boehringer Ingelheim Investigational Site
City
Pune, Maharashtra
Country
India
Facility Name
1160.71.1110 Boehringer Ingelheim Investigational Site
City
Afula
Country
Israel
Facility Name
1160.71.1121 Boehringer Ingelheim Investigational Site
City
Afula
Country
Israel
Facility Name
1160.71.1111 Boehringer Ingelheim Investigational Site
City
Ashkelon
Country
Israel
Facility Name
1160.71.1117 Boehringer Ingelheim Investigational Site
City
Givatayim
Country
Israel
Facility Name
1160.71.1112 Boehringer Ingelheim Investigational Site
City
Hadera
Country
Israel
Facility Name
1160.71.1091 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1160.71.1113 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1160.71.1114 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1160.71.1116 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1160.71.1118 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1160.71.1105 Boehringer Ingelheim Investigational Site
City
Holon
Country
Israel
Facility Name
1160.71.1101 Boehringer Ingelheim Investigational Site
City
Jerusalem
Country
Israel
Facility Name
1160.71.1104 Boehringer Ingelheim Investigational Site
City
Jerusalem
Country
Israel
Facility Name
1160.71.1106 Boehringer Ingelheim Investigational Site
City
Jerusalem
Country
Israel
Facility Name
1160.71.1119 Boehringer Ingelheim Investigational Site
City
Kfar Saba
Country
Israel
Facility Name
1160.71.1096 Boehringer Ingelheim Investigational Site
City
Petah Tikva
Country
Israel
Facility Name
1160.71.1093 Boehringer Ingelheim Investigational Site
City
Ramat Gan
Country
Israel
Facility Name
1160.71.1094 Boehringer Ingelheim Investigational Site
City
Ramat Gan
Country
Israel
Facility Name
1160.71.1095 Boehringer Ingelheim Investigational Site
City
Ramat Gan
Country
Israel
Facility Name
1160.71.1100 Boehringer Ingelheim Investigational Site
City
Rehovot
Country
Israel
Facility Name
1160.71.1103 Boehringer Ingelheim Investigational Site
City
Safed
Country
Israel
Facility Name
1160.71.1120 Boehringer Ingelheim Investigational Site
City
Tel Aviv
Country
Israel
Facility Name
1160.71.1122 Boehringer Ingelheim Investigational Site
City
Tel Aviv
Country
Israel
Facility Name
1160.71.1107 Boehringer Ingelheim Investigational Site
City
Tel-Aviv
Country
Israel
Facility Name
1160.71.1108 Boehringer Ingelheim Investigational Site
City
Tel-Aviv
Country
Israel
Facility Name
1160.71.1109 Boehringer Ingelheim Investigational Site
City
Tel-Aviv
Country
Israel
Facility Name
1160.71.1169 Boehringer Ingelheim Investigational Site
City
Arezzo
Country
Italy
Facility Name
1160.71.1172 Boehringer Ingelheim Investigational Site
City
Ascoli Piceno
Country
Italy
Facility Name
1160.71.1170 Boehringer Ingelheim Investigational Site
City
Sassari
Country
Italy
Facility Name
1160.71.1585 Boehringer Ingelheim Investigational Site
City
Busan
Country
Korea, Republic of
Facility Name
1160.71.1586 Boehringer Ingelheim Investigational Site
City
Cheonan-si
Country
Korea, Republic of
Facility Name
1160.71.1584 Boehringer Ingelheim Investigational Site
City
Daegu
Country
Korea, Republic of
Facility Name
1160.71.1591 Boehringer Ingelheim Investigational Site
City
Daegu
Country
Korea, Republic of
Facility Name
1160.71.1590 Boehringer Ingelheim Investigational Site
City
Gwangju
Country
Korea, Republic of
Facility Name
1160.71.1581 Boehringer Ingelheim Investigational Site
City
Incheon
Country
Korea, Republic of
Facility Name
1160.71.1582 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.71.1583 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.71.1589 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.71.1592 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.71.1593 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1160.71.1291 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
1160.71.1292 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
1160.71.1337 Boehringer Ingelheim Investigational Site
City
's Hertogenbosch
Country
Netherlands
Facility Name
1160.71.1344 Boehringer Ingelheim Investigational Site
City
Almelo
Country
Netherlands
Facility Name
1160.71.1331 Boehringer Ingelheim Investigational Site
City
Amsterdam
Country
Netherlands
Facility Name
1160.71.1336 Boehringer Ingelheim Investigational Site
City
Apeldoorn
Country
Netherlands
Facility Name
1160.71.1332 Boehringer Ingelheim Investigational Site
City
Breda
Country
Netherlands
Facility Name
1160.71.1349 Boehringer Ingelheim Investigational Site
City
Den Helder
Country
Netherlands
Facility Name
1160.71.1345 Boehringer Ingelheim Investigational Site
City
Deventer
Country
Netherlands
Facility Name
1160.71.1360 Boehringer Ingelheim Investigational Site
City
Dirksland
Country
Netherlands
Facility Name
1160.71.1340 Boehringer Ingelheim Investigational Site
City
Ede
Country
Netherlands
Facility Name
1160.71.1358 Boehringer Ingelheim Investigational Site
City
Eindhoven
Country
Netherlands
Facility Name
1160.71.1338 Boehringer Ingelheim Investigational Site
City
Enschede
Country
Netherlands
Facility Name
1160.71.1343 Boehringer Ingelheim Investigational Site
City
Goes
Country
Netherlands
Facility Name
1160.71.1347 Boehringer Ingelheim Investigational Site
City
Gorinchem
Country
Netherlands
Facility Name
1160.71.1333 Boehringer Ingelheim Investigational Site
City
Groningen
Country
Netherlands
Facility Name
1160.71.1361 Boehringer Ingelheim Investigational Site
City
Heerlen
Country
Netherlands
Facility Name
1160.71.1339 Boehringer Ingelheim Investigational Site
City
Hengelo
Country
Netherlands
Facility Name
1160.71.1346 Boehringer Ingelheim Investigational Site
City
Hilversum
Country
Netherlands
Facility Name
1160.71.1356 Boehringer Ingelheim Investigational Site
City
Hoorn
Country
Netherlands
Facility Name
1160.71.1359 Boehringer Ingelheim Investigational Site
City
Maastricht
Country
Netherlands
Facility Name
1160.71.1341 Boehringer Ingelheim Investigational Site
City
Meppel
Country
Netherlands
Facility Name
1160.71.1354 Boehringer Ingelheim Investigational Site
City
Rotterdam
Country
Netherlands
Facility Name
1160.71.1351 Boehringer Ingelheim Investigational Site
City
Sneek
Country
Netherlands
Facility Name
1160.71.1353 Boehringer Ingelheim Investigational Site
City
Tiel
Country
Netherlands
Facility Name
1160.71.1352 Boehringer Ingelheim Investigational Site
City
Tilburg
Country
Netherlands
Facility Name
1160.71.1350 Boehringer Ingelheim Investigational Site
City
Veldhoven
Country
Netherlands
Facility Name
1160.71.1342 Boehringer Ingelheim Investigational Site
City
Velp
Country
Netherlands
Facility Name
1160.71.1348 Boehringer Ingelheim Investigational Site
City
Zwijndrecht
Country
Netherlands
Facility Name
1160.71.1396 Boehringer Ingelheim Investigational Site
City
Gjøvik
Country
Norway
Facility Name
1160.71.1393 Boehringer Ingelheim Investigational Site
City
Moss
Country
Norway
Facility Name
1160.71.1395 Boehringer Ingelheim Investigational Site
City
Nordbyhagen
Country
Norway
Facility Name
1160.71.1391 Boehringer Ingelheim Investigational Site
City
Oslo
Country
Norway
Facility Name
1160.71.1397 Boehringer Ingelheim Investigational Site
City
Oslo
Country
Norway
Facility Name
1160.71.1394 Boehringer Ingelheim Investigational Site
City
RUD
Country
Norway
Facility Name
1160.71.1422 Boehringer Ingelheim Investigational Site
City
Ermita Manila
Country
Philippines
Facility Name
1160.71.1421 Boehringer Ingelheim Investigational Site
City
Manila
Country
Philippines
Facility Name
1160.71.1424 Boehringer Ingelheim Investigational Site
City
Pasig City
Country
Philippines
Facility Name
1160.71.1423 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
1160.71.1425 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
1160.71.1436 Boehringer Ingelheim Investigational Site
City
Gdynia
Country
Poland
Facility Name
1160.71.1437 Boehringer Ingelheim Investigational Site
City
Gdynia
Country
Poland
Facility Name
1160.71.1438 Boehringer Ingelheim Investigational Site
City
Gdynia
Country
Poland
Facility Name
1160.71.1433 Boehringer Ingelheim Investigational Site
City
Pulawy
Country
Poland
Facility Name
1160.71.1431 Boehringer Ingelheim Investigational Site
City
Warsaw
Country
Poland
Facility Name
1160.71.1432 Boehringer Ingelheim Investigational Site
City
Warsaw
Country
Poland
Facility Name
1160.71.1434 Boehringer Ingelheim Investigational Site
City
Zabrze
Country
Poland
Facility Name
1160.71.1456 Boehringer Ingelheim Investigational Site
City
Amadora
Country
Portugal
Facility Name
1160.71.1451 Boehringer Ingelheim Investigational Site
City
Carnaxide
Country
Portugal
Facility Name
1160.71.1454 Boehringer Ingelheim Investigational Site
City
Coimbra
Country
Portugal
Facility Name
1160.71.1459 Boehringer Ingelheim Investigational Site
City
Coimbra
Country
Portugal
Facility Name
1160.71.1457 Boehringer Ingelheim Investigational Site
City
Covilhã
Country
Portugal
Facility Name
1160.71.1455 Boehringer Ingelheim Investigational Site
City
Porto
Country
Portugal
Facility Name
1160.71.1471 Boehringer Ingelheim Investigational Site
City
Bucharest
Country
Romania
Facility Name
1160.71.1472 Boehringer Ingelheim Investigational Site
City
Bucharest
Country
Romania
Facility Name
1160.71.1501 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.71.1503 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.71.1504 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.71.1505 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.71.1507 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.71.1508 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.71.1509 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.71.1510 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.71.1511 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1160.71.1512 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1160.71.1513 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1160.71.1514 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1160.71.1531 Boehringer Ingelheim Investigational Site
City
Singapore
Country
Singapore
Facility Name
1160.71.1548 Boehringer Ingelheim Investigational Site
City
Banska Bystrica
Country
Slovakia
Facility Name
1160.71.1541 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1160.71.1542 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1160.71.1543 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1160.71.1550 Boehringer Ingelheim Investigational Site
City
Kosice
Country
Slovakia
Facility Name
1160.71.1547 Boehringer Ingelheim Investigational Site
City
Zilina
Country
Slovakia
Facility Name
1160.71.1633 Boehringer Ingelheim Investigational Site
City
Göteborg
Country
Sweden
Facility Name
1160.71.1627 Boehringer Ingelheim Investigational Site
City
Malmö
Country
Sweden
Facility Name
1160.71.1625 Boehringer Ingelheim Investigational Site
City
Norrköping
Country
Sweden
Facility Name
1160.71.1628 Boehringer Ingelheim Investigational Site
City
Nässjö
Country
Sweden
Facility Name
1160.71.1626 Boehringer Ingelheim Investigational Site
City
Stockholm
Country
Sweden
Facility Name
1160.71.1634 Boehringer Ingelheim Investigational Site
City
Stockholm
Country
Sweden
Facility Name
1160.71.1624 Boehringer Ingelheim Investigational Site
City
Umeå
Country
Sweden
Facility Name
1160.71.1621 Boehringer Ingelheim Investigational Site
City
Uppsala
Country
Sweden
Facility Name
1160.71.1635 Boehringer Ingelheim Investigational Site
City
Uppsala
Country
Sweden
Facility Name
1160.71.1622 Boehringer Ingelheim Investigational Site
City
Västerås
Country
Sweden
Facility Name
1160.71.1623 Boehringer Ingelheim Investigational Site
City
Örebro
Country
Sweden
Facility Name
1160.71.1652 Boehringer Ingelheim Investigational Site
City
Basel
Country
Switzerland
Facility Name
1160.71.1655 Boehringer Ingelheim Investigational Site
City
Bellinzona
Country
Switzerland
Facility Name
1160.71.1651 Boehringer Ingelheim Investigational Site
City
Bern
Country
Switzerland
Facility Name
1160.71.1654 Boehringer Ingelheim Investigational Site
City
Lugano
Country
Switzerland
Facility Name
1160.71.1680 Boehringer Ingelheim Investigational Site
City
Changhua
Country
Taiwan
Facility Name
1160.71.1683 Boehringer Ingelheim Investigational Site
City
Hualien
Country
Taiwan
Facility Name
1160.71.1682 Boehringer Ingelheim Investigational Site
City
Kaohsiung
Country
Taiwan
Facility Name
1160.71.1679 Boehringer Ingelheim Investigational Site
City
Taichung
Country
Taiwan
Facility Name
1160.71.1681 Boehringer Ingelheim Investigational Site
City
Tainan
Country
Taiwan
Facility Name
1160.71.1671 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.71.1672 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.71.1673 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.71.1674 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.71.1675 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.71.1676 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.71.1677 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1160.71.1678 Boehringer Ingelheim Investigational Site
City
Taoyuan
Country
Taiwan
Facility Name
1160.71.1701 Boehringer Ingelheim Investigational Site
City
Bangkok
Country
Thailand
Facility Name
1160.71.1703 Boehringer Ingelheim Investigational Site
City
Chiang Mai
Country
Thailand
Facility Name
1160.71.1704 Boehringer Ingelheim Investigational Site
City
Khon Kaen
Country
Thailand
Facility Name
1160.71.1744 Boehringer Ingelheim Investigational Site
City
Birmingham
Country
United Kingdom
Facility Name
1160.71.1746 Boehringer Ingelheim Investigational Site
City
Chertsey
Country
United Kingdom
Facility Name
1160.71.1745 Boehringer Ingelheim Investigational Site
City
County Armagh
Country
United Kingdom
Facility Name
1160.71.1755 Boehringer Ingelheim Investigational Site
City
Kirkcaldy, Fife
Country
United Kingdom
Facility Name
1160.71.1741 Boehringer Ingelheim Investigational Site
City
London
Country
United Kingdom
Facility Name
1160.71.1742 Boehringer Ingelheim Investigational Site
City
Newcastle upon Tyne
Country
United Kingdom
Facility Name
1160.71.1751 Boehringer Ingelheim Investigational Site
City
Newport
Country
United Kingdom
Facility Name
1160.71.1752 Boehringer Ingelheim Investigational Site
City
Northampton
Country
United Kingdom
Facility Name
1160.71.1743 Boehringer Ingelheim Investigational Site
City
Romford, Essex
Country
United Kingdom
Facility Name
1160.71.1748 Boehringer Ingelheim Investigational Site
City
York
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
23770747
Citation
Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013 Jul 16;128(3):237-43. doi: 10.1161/CIRCULATIONAHA.112.001139. Epub 2013 Jun 14.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1160/1160.71_U13-3509-01-DS.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1160/1160.71_Literature.pdf
Description
Related Info

Learn more about this trial

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

We'll reach out to this number within 24 hrs